Washington University in St. Louis

Washington University Open Scholarship
All Theses and Dissertations (ETDs)
5-24-2009

Integrated Genomics Of Susceptiblity To Therapy-Related
Leukemia
Patrick Cahan
Washington University in St. Louis

Follow this and additional works at: https://openscholarship.wustl.edu/etd

Recommended Citation
Cahan, Patrick, "Integrated Genomics Of Susceptiblity To Therapy-Related Leukemia" (2009). All Theses
and Dissertations (ETDs). 882.
https://openscholarship.wustl.edu/etd/882

This Dissertation is brought to you for free and open access by Washington University Open Scholarship. It has
been accepted for inclusion in All Theses and Dissertations (ETDs) by an authorized administrator of Washington
University Open Scholarship. For more information, please contact digital@wumail.wustl.edu.

WASHINGTON UNIVERSITY IN ST. LOUIS
Division of Biology and Biomedical Sciences
Computational Biology

Dissertation Examination Committee:
Timothy Graubert, Chair
Michael Brent
Timothy Ley
Howard McLeod
Rakesh Nagarajan
Nancy Saccone

INTEGRATED GENOMICS OF SUSCEPTIBLITY TO THERAPY-RELATED LEUKEMIA

by

Patrick Cahan

A dissertation presented to the
Graduate School of Arts and Sciences
of Washington University in
partial fulfillment of the
requirements for the degree
of Doctor of Philosophy

December 2009
Saint Louis, Missouri

Acknowledgements
My thesis advisor, Dr. Tim Graubert, has been a constant source of motivation and scientific
insight. Our many discussions, in which Tim would share his incisive logic in breaking down a
problem or a faulty line of reasoning, have made me a better scientist. When my energy or
enthusiasm for a particular project would begin to wane, Tim would intuit this and help, however
possible, to move things forward. Everyone in his lab has benefited greatly from the unique
learning environment that he has created. Thank you, Tim.
I am grateful for the time, effort and thought that members of the thesis committee have
offered: Dr. Michael Brent, Dr. Tim Ley, Dr. Howard McLeod, Dr. Rakesh Nagarajan, and Dr.
Nancy Saccone. Through committee meetings and discussions I have gained both insight into
technical aspects of my project and an appreciation for the power of bringing together diverse
expertise. I would especially like to thank Tim Ley for leading and sustaining the vibrant
intellectual community that is the 6th floor, and for providing many opportunities for me to expand
my experience beyond the immediate scope of my thesis work. I am grateful to Howard McLeod
for initially taking on the mentorship of a computational biologist in a predominantly wet lab, and
for subsequently looking out for my development and career in a selfless way. I am also grateful
to both Michael Brent and Nancy Saccone for taking the time outside of committee meetings to
discuss technical aspects of my thesis work. I would also like to thank Michael for serving as
thesis committee chair.
I would like to express thanks to previous and current Graubert lab members, including
Julie Fortier, Ryan Funk, Megan Janke, Masayo Izumi, Yedda Li, Elise Peterson Lu, Theresa
(Treeza) Okeyo-Owuor, and Richard Walgren for their helpful comments, discussions, technical
help, and tolerance and patience. You have made it engaging, educational, and fun to be in the
lab. I would like to especially thank Masayo for her critical role in many of the experiments in this
thesis work. Without her diligent consistence, much of this work would not have been possible. I
would also like the thank Yedda Li for her significant and insightful contributions to the CNV
validation work. I would also like to thank Julie Fortier for lending her expert knowledge and
training me in several wet lab experiments. I would be remiss if I did not thank Bill Eades, Jackie

ii

Hughes, Chris Holley, and Bill Lamberton in the High Speed Cell Sorter Core. They have been
patient and accommodating when my preparations took longer than predicted (almost always),
and their expertise was critical to the success of my thesis work. I also thank Bill Eades for the
extended use of a computer.
I would like to acknowledge support from the NIH Genome Analysis Training Program
and Kauffman Fellowship Pathway in Life Sciences Entrepreneurship.
My parents, Joe and Jane Cahan, are awesome. From the beginning, they have
provided me with every opportunity to grow and learn. They have instilled in me a curiosity about
the world, and a confidence to go and explore it. Thank you, Mom and Dad! I am also thankful to
my brothers Josh and Matt, who have always looked out for me, have been supportive through
this journey, and who never fail to make me laugh.
This dissertation is dedicated to my wife, Moira Nealon Cahan. Through the past 5+
years of graduate school, she has been a source of constant support. I thank Moira for the many
sacrifices that she has made so that I could pursue this dream of becoming a scientist and for
making sure that I always ‘keep it real’.

iii

Table of Contents

Acknowledgements ………………………………………………………………………….. ii
Table of Contents ……………………………………………………………………………. iv
List of Tables …………………………………………………………………………………. vi
List of Figures ………………………………………………………………………………... vii
Abstract of the Dissertation ………………………………………………………………... ix
Chapter 1: Introduction
Therapy-related Acute Myeloid Leukemia ………………………………. 1
Integrated Genomics ............................………………………………...... 4
DNA Copy Number Variation .................……………………………….… 5
References …………............................……………………………….….. 9
Chapter 2: WuHMM: a robust algorithm to detect DNA copy number variation
Using long oligonucleotide microarray data ....……………….…... 15
Abstract …….……………………………………………………………….. 16
Introduction ….……………………………………………………………… 17
Materials and Methods ….………………………………………………… 19
Results …………………….………………………………………………… 26
Discussion ………………….………………………………………………. 33
Funding ……………………….…………………………………………….. 35
Acknowledgements ………….…………………………………………….. 36
References …………………….……………………………………………. 41
Chapter 3: The impact of copy number variation on local gene expression in
mouse hematopoietic stem and progenitor cells .......…………….. 65
Abstract …………………………………………………………………….. 66
Introduction ………………………………………………………………… 67
Results ………………………………………………………………….….. 68
Discussion …………………………………………………………….…… 77
Methods ……………………………………………………………….…… 79

iv

Acknowledgements ………………………………………………….……. 85
References ………………………………………………………………… 86

Chapter 4: Integrated genomics of susceptibility to therapy-related leukemia ... 112
Introduction ……………………………………………………………….. 113
Results …………………………………………………………………….. 115
Discussion ………………………………………………………………… 119
Methods …………………………………………………………………… 124
References ………………………………………………………………... 149

Chapter 5: Conclusion ……………………………………………………………………. 152
DNA Copy Number Variation …………………………………………... 152
Therapy-related AML ……………………………………………………. 154
References ……………………………………………………………….. 156

v

List of Tables

Chapter 2
Table 2.1: Relationship between sequence identity and aCGH signal…………… 37
Table 2.2: Detection of singletons and doubletons on 385K-aCGH ……………… 38
Table 2.3: Effective resolution of aCGH platforms analyzed by wuHMM ….…….. 39
Table 2.4: Performance of segmentation algorithms on 385K-aCGH data ……… 40

Chapter 3
Table 3.1: CNVR eQTL characteristics ……………………………………………… 89
Table 3.2: Subset of CNVR-eQTLs in hematopoietic stem and progenitor cells,
hypothalamus, and adipose tissues ………………..………………………. 90

Chapter 4
Table 4.1: Functional Enrichment of Differentially Expressed Genes …………… 128
Table 4.2: Anchored Susceptibility Modules ……………………………………….. 129

vi

List of Figures
Chapter 1
Figure 1.1: Flow chart of integrated genomics methodology for identification of
candidate network underlying susceptibility …………………………………. 7

Chapter 2
Figure 2.1: wuHMM ………………………………………………………………….….. 45
Figure 2.2: 3.1M-aCGH log2-ratio plot of 129X1/SvJ chromosome 7 ………….….. 47
Figure 2.3: Receiver Operating Curves characterize the performance of
wuHMM …………………………………………………………………………. 49
Figure 2.4: Performance differences between wuHMM with sequence
divergence and without sequence divergence ……………………………… 51
Figure 2.5: Validation of selected 3.1M-aCGH CNV calls in 129X1/SvJ ………….. 53
Supplementary Figure S2.1: Genome partitioning by sequence divergence
as determined using SNP genotype calls …………………………………… 55
Supplementary Figure S2.2: Ranking probes by cluster ……………………………. 57
Supplementary Figure S2.3: Invalidated calls ……………………………………….. 59
Supplementary Figure S2.4: Comparison of threshold criteria …………………….. 61
Supplementary Figure S2.5: Noise penalty performance comparison of
wuHMM without using sequence information ……………………………… 63

Chapter 3
Figure 3.1: CNVR genotyping ………………………………………………………….. 91
Figure 3.2: Location of CNVRs in the inbred mouse genome ……………………… 93
Figure 3.3: Distribution of CNVR sizes ………………………………………………... 95
Figure 3.4: Co-localization of CNVRs with other genomic elements ………………. 97
Figure 3.5: Tissue-specific CNVR eQTLs …………………………………………….. 99
Figure 3.6: CNVR eQTLs ………………………………………………………………. 101

vii

Supplementary Figure S3.2: Distribution of copy number variable sequence
content by CNVR size across strains ………………………………………. 104
Supplementary Figure S3.3: Validation of cell sort purity by gene expression
profile ………………………………………………………………………….. 106
Supplementary Figure S3.4: Relationship between CNVR and eQTL by
distance and effect size ……………………………………………………… 108
Supplementary Figure S3.5: Concordance between CNVRs and individual
CNV boundaries ……………………………………………………………… 110
Chapter 4
Figure 4.1: Mouse Haplotype Map …………………………………………………… 130
Figure 4.2: Gene Expression Profiling of Hematopoietic Stem and Progenitor
Cells in t-AML Resistant and Susceptible Strains of Mice………………... 132
Figure 4.3: Anchored Susceptibility Networks ………………………………………. 135
Supplementary Figure S4.1: Strain Dendrograms ………………………………….. 140
Supplementary Figure S4.2: Differential Gene Expression …..……………………. 145
Supplementary Figure S4.3: Gene Expression Profiling of Hematopoietic Cells
from BXD Mice ……..………………………………………………………… 147

viii

ABSTRACT OF THE DISSERTATION
Integrated Genomics of Susceptibility to
Therapy-related Leukemia
by
Patrick Cahan
Doctor of Philosophy in Biology and Biomedical Sciences (Computational Biology)
Washington University in St. Louis, 2009
Professor Timothy Graubert, Chair

Therapy-related acute myeloid leukemia t-AML is a secondary, generally incurable,
malignancy attributable to the chemotherapeutic treatment of an initial disease. Although there is
a genetic component to susceptibility to therapy-related leukemias in mice, little is understood
either about the contributing loci, or the mechanisms by which susceptibility factors mediate their
effect. An improved understanding of susceptibility factors and the biological processes in which
they act may lead to the development of t-AML prevention strategies.
In this thesis work, we identified expression networks that are associated with t-AML
susceptibility in mice. These networks are robust in that they emerge from distinct methods of
analysis and from different gene expression data sets of hematopoietic stem and progenitor
lineages. These networks are enriched in genes involved in cell cycle and DNA repair,
suggesting that these processes play a role in susceptibility. By integrating gene expression and
genetic information we prioritized network nodes for experimental validation as contributors to
expression networks and t-AML susceptibility.
Network analysis and node prioritization required a comprehensive map of genetic
variation in mouse, which was not available at the outset of this thesis work. Specifically, DNA
copy number variations (CNVs), defined as genomic sequences that are polymorphic in copy
number and range in length from 1,000 to several million base pairs, were largely
uncharacterized in inbred mice. We developed a computational approach, Washington University
Hidden Markov Model (wuHMM), to identify CNVs from high-density array comparative genomic
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hybridization data, accounting for the high degree of polymorphism that occur between mouse
strains. Using wuHMM we analyzed the copy number content of the mouse genome (20 strains)
to a sub-10-kb resolution, finding over 1,300 CNV-regions (CNVRs), most of which are < 10 kb in
length, are found in more than one strain, and span 3.2% (85 Mb) of the reference genome.
These CNVRs, along with haplotype blocks we derived from publicly available SNP data, were
integrated into susceptibility expression network analysis. In addition to addressing questions
regarding t-MDS/AML susceptibility, we also used this data to assess the potential functional
impact of copy number variation by mapping expression profiles to CNVRs. In hematopoietic
stem and progenitor cells, up to 28% of strain-dependent expression variation is associated with
copy number variation, supporting the role of germline CNVs as key contributors to natural
phenotypic variation.

x

Therapy-related Acute Myeloid Leukemia (t-AML)

Acute myeloid leukemia (AML) is a clonal malignancy characterized by the accumulation of
immature leukocytes in the bone marrow. The associated disruption of hematopoiesis in AML
patients reduces the number of red blood cells (anemia), neutrophils (neutropenia), and platelets
(thrombocytopenia), and leads to complications arising from the loss of proper function of these
cell types. Untreated AML is fatal, but with chemotherapy the survival rate for those under 65 is
approximately 40%1. Frequent chromosomal abnormalities in AML include t(8;21), resulting in
the AML1-ETO fusion gene, translocations involving chr11q23, which harbors the Mixed-Lineage
Leukemia (MLL) gene, to a variety of other sites, t(15;17) resulting in the PML_RARα fusion
gene, and structural re-arrangements of chr16. However, none of these events are sufficient to
cause leukemia. The identification of cooperating mutations promises to lead to a better
understanding of this heterogeneous disease and, eventually, to improved treatments. Important
advances in this field are being made by whole genome re-sequencing efforts, where mutations
in genes not previously linked to cancer have been identified2,3.
Therapy-related acute myeloid leukemia (t-AML) is a secondary malignancy attributable
to the chemotherapeutic and/or radiotherapeutic treatment of a variety of diseases, including
hematological and solid tumors. Therapy-AML does not exclusively reflect a predisposition to
sporadic AML because t-AML occurs in patients treated for autoimmune disorders such as
rheumatoid arthritis and multiple sclerosis (Karran 2003). The incidence of t-AML ranges widely
depending on study and primary disease. Of breast cancer survivors, 1.7% develop secondary
bone marrow diseases4. Of lymphoma and Hodgkin disease patients, 5-20% go on to acquire tAML5. Although arguably distinct diseases, 80% of t-AML cases are preceded by therapy-related
myelodysplastic syndromes and in this thesis I will refer to them as a single entity (t-AML).
Therapy-AML typically appears three to ten years after initial chemotherapy. Common
cytogenetic events associated with t-AML are loss of all or part of chromosomes 5 and/or 7
(70%)6. Therapy-AML comprise 5-20% of all AML cases and their prevalence is increasing along
with the population undergoing chemotherapy7,8. t-AML are generally incurable9. Median survival
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time from diagnosis is eight months and survival time for associated with the combined chr5/chr7
loss karyotypes is 5 months10. It is 11 months for those with no karyotypic abnormalities6.
Currently, hematopoietic stem cell transplant (HCT) the only cure but often is infeasible and risky
as there is a 49% transplant-related mortality11. Complete remission of t-AML occurs in 28% of
patients treated versus 65-80% in primary AML12. Differences in response are due to a variety of
factors, including persistence of primary disease, tissue/organ damage by treatment (bone
marrow stroma, depletion of HSC), immunosuppression and resulting infections. Because t-AML
is a clinically induced malignancy, it is, by definition, preventable. Therefore, a long-term goal of
t-AML research is to gain sufficient understanding of susceptibility factors in order to make
worthwhile the personalization of chemotherapeutic regiments based on t-AML risk. Also,
because t-AML shares many characteristics with its primary counterpart, an understanding of tAML susceptibility may provide insight into the etiology of primary AML and progression from
MDS.
Approximately 75% of t-AML cases are associated with prior alkylator treatment (i.e.,
melphalan, busulfan, thiotepa)10. The therapeutic effect of alkylator agents is believed to result
from the formation of DNA adducts and single and double-strand breaks, which trigger apoptosis
or growth arrest13. The precise mechanisms of action are unclear, as are the effects of alkylators
on RNA and protein. Topoisomerase II inhibitors (i.e., etoposide, doxorubicin, mitoxantrone) also
cause therapy-related leukemias distinct from those induced by alkylators: there is a shorter
latencies (1-3 years), a preceding phase of MDS is infrequent, and tumors often contain chr11q23
translocations and other translocations, but not complete or partial loss of chr5/7. The focus of
the current work is susceptibility to alkylator-induced AML. However, it is likely that many of the
methods and resources developed here will be directly applicable to investigate the susceptibility
to secondary malignancies due to topoisomerase II exposure.
Therary-AML is not due entirely to the stochastic nature of therapy-induced mutations.
Contributing factors to this complex phenotype include the primary disease8, the cumulative dose
of chemotherapy14, and genetic background15. There are rare, familial cancer predisposition
syndromes with mutations in TP5316, XPD17, or NF118 that increase t-AML susceptibility. Beyond
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these rare cases, it has been hypothesized susceptibility is a complex trait in that inherited
polymorphisms in multiple genes each contribute a small amount to overall susceptibility status.
Based on the presumed genotoxic mechanism of alkylators, genes involved in DNA repair19,
response to oxidative stress20, and drug metabolism21 have been investigated as mediators of
susceptibility in candidate gene studies. While many studies have been performed, the results
have been either conflicting, inconclusive, or find relative weak effect sizes22. A notable limitation
of most candidate gene studies to date is that they have focused on polymorphisms believed to
result in (non-conservative) changes in the protein sequence.
Perhaps the most promising approaches to identify genes and pathways involved in
susceptibility are unbiased, genome-wide methods. One of the first genome-wide studies was
performed leveraging genetic variation across an inbred panel of mice as a disease susceptibility
model23. In this study, eight to twelve individual mice from each of 20 inbred strains were treated
with the alkylating agent N-nitroso-N-ethylurea (ENU), a potent mutagen with a propensity to
cause AT:TA transversions and AT:GC transitions24. Mice were monitored for the development of
MDS and AML for up to 16 months post ENU exposure. Myeloid tumors varied by strain,
supporting the hypothesis of a strong genetic component in t-AML susceptibility (estimated to be
0.10). This study also used the in silico mapping method to identify two genomic intervals
associated with susceptibility. A follow-up study of an F2 cross of susceptible and resistant
parental strains identified thirteen quantitative trait loci (QTLs) associated with the t-AML traits,
including leukemia-free survival time, white blood cell count, and spleen weight25. These studies
have demonstrated that susceptibility in inbred mice is not purely stochastic. Further, they have
identified candidate loci. Although the QTLs do not coincide between the two studies, they have
served as starting points to identify quantitative trait genes. A limitation of these approaches (and
in mapping any QTL) is the difficulty in narrowing QTLs down to quantitative trait genes, which
can take many years and has been successful in approximately 20 out of over 2,000 QTLs
reported as of 200526.

3

Integrated genomics

Relatively unbiased, genome wide approaches such as genome-wide association studies
(GWAS) hold great promise to reveal much about complex traits in human populations. They are
similar to candidate gene studies in that they compare the relative frequencies of polymorphisms
between case and control groups. Unlike candidate gene studies, GWAS use panels of markers
that span the genome and capture a large fraction of SNP variation (this varies depending on the
population assayed and platform used). Recent genome wide association studies have identified
candidate susceptibility loci for several cancers: 29 in prostate cancer27-33, 13 in breast cancer34, 10 in colon cancer39-41. Most loci identified to date are non-overlapping between cancer types,
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suggesting that tissue specific forces are important in cancer susceptibility42. In contrast to
sporadic cancers, for cancers associated with exposure (i.e., lung cancer) only a handful of loci
have been found: 3 in lung cancer43-45 and 3 in bladder cancer46,47. Whether this means that
susceptibility to exposure-based cancers has a more modest genetic component remains to be
determined. In a recent GWAS, more associations with t-AML were detected than would be
expected by chance, even given the relatively small number of individuals in the study48 (80
cases, 150 controls). None of the three validated candidate SNPs had previously been
implicated in susceptibility previously. A drawback to GWAS studies, especially in light of the
apparent complexity of cancer susceptibility, is the low power to detect weak effects. A second
drawback is that even when association studies are successful, mechanisms linking candidate
variants to susceptibility are not readily apparent. For example, the ApoE E4 genotype has been
known as a risk factor for late-onset Alzheimer’s for more than ten years and yet the mechanism
by which it contributes to the disease remains unknown49.
Evidence is accumulating that many genetic contributors to complex traits are not proteincoding changes50. If true, then the only other class of genetic events that can effect phenotype
must, at some level, impact expression (i.e. eQTLs). Combining information from expression
profiling experiments and genetic association studies can identify such events (i.e. eQTLs that
contribute to disease/complex traits) involved in myocardial calcification51, atherosclerosis52 and
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obesity (proposed in 53, candidates discovered in 54, causal genes validated in 55). By augmenting
these approaches with network analysis, it is possible to extend the insight of integrated studies
to a better understanding of the molecular underpinnings of complex phenotypes56,57. These
approaches can be further extended by comparing networks across species, which has practical
benefits in terms of initial tests of candidate targets58. The work described in this thesis applies
an integrative genomics approach to identify and prioritize genetic and transcriptional networks
underlying t-AML susceptibility (Figure 1).

DNA copy number variation

In contrast to previous integrated genomics work, this thesis explicitly includes information on
DNA copy number variations. Copy number variants (CNVs), currently defined as genomic
sequences greater than one kilobase that are polymorphic in copy number59, have been identified
in diverse species including human, chimp, rat, mouse, and drosophila60-79. In the short interval
since the discovery of wide-spread copy number variation in apparently healthy individuals, there
has been rapid expansion of both CNV detection techniques and their application across a range
of biological samples and species. From these studies, it is apparent that copy number variation
exceeds single nucleotide polymorphisms (SNPs) as a source of genetic variation, and that many
CNVs contain or overlap genes and, thereby, may have functional effects. However, the role of
copy number variation in mediating both ‘normal’ phenotypic variation and disease susceptibility
is only beginning to emerge. Fundamental questions about the nature and impact of CNVs
remain unanswered, mainly due to methodological constraints. In this thesis work, we set out to
determine the copy number variable content of the mouse genome so that this information could
be included in the integrated genomics study of t-AML susceptibility. Further, we estimated its
functional impact, as measured by gene expression profiling in vivo.
At the time this thesis work began, the genome-wide discovery of CNVs was limited to
large (>20 kb) events due to technological constraints. In order to accurately assess the impact
of copy number variation on phenotype, as well as to learn more about their fine structure and
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origins, it is necessary to reliably detect CNVs of all sizes and accurately determine their genomic
boundaries. Currently, the most common genome-wide approaches to identify CNVs are arraybased. These platforms include bacterial artificial chromosome (BAC) array comparative
genomic hybridization (aCGH)80,81, long oligonucleotide arrays 82-84 and single nucleotide
polymorphism (SNP) genotyping arrays85. A critical aspect in selecting a platform for CNV
detection is effective resolution, which we define as the length of the shortest CNV that is
detectable at an acceptable false positive rate (FPR). A number of factors contribute to
resolution, including probe density (i.e., the number of probes that interrogate a region of the
genome), probe specificity and sensitivity. Due to their high probe density, long oligonucleotide
arrays theoretically have the highest resolution and genome coverage of the three array-based
platforms86,87. However, the higher level of noise of these platforms86,88 has hampered efforts to
mine these data for novel CNVs using available analytical tools, which were designed for BACarray analysis. At the time this thesis work began, there was only one published account of a
method designed specifically for detecting CNVs from such data89 but there has been no
comprehensive analysis of the achievable genome-wide resolution of these platforms. As a
prerequisite to mapping common CNVs in inbred mice, estimating their impact on expression,
and including them in integrated genomics studies of t-AML susceptibly, we first set out to
develop a method for detecting CNVs specifically from long-oligo aCGH data. This CNV
detection work constitutes the first phase of this dissertation project, as described in the next
chapter
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genes and
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Figure 1: Flow chart of integrated genomics methodology for identification of candidate network
underlying susceptibility. DNA and RNA are collected from 20 inbred strains of mice, 15 of which
vary in susceptibility to alkylator induced AML. DNA is hybridized to aCGH arrays for detection of
CNVs. SNPs genotypes downloaded from a public repository (Broad) are used to generate a
haplotype map of 48 classical inbred strains of mice (superset of the 20 strains assayed for CNV).
RNA is used for gene expression profiling to (1) determine genes that are differentially expressed
between t-AML susceptible and resistant strains, and (2) to map expression traits to CNVs and
haplotypes, in cis. Expression quantitative traits that do not replicate in independent data are
removed from further analysis. Genes that are both differentially expressed between susceptible
and resistant strains, and are linked to a validated eQTL are termed ‘anchors’. Anchored
coexpression networks are derived for each anchor by identifying all genes that have significantly
correlated expression profiles to the anchor. Networks are trimmed of all genes that do not have
reproducible association with anchor gene expression in independent data. Anchored
coexpression networks are prioritized for downstream experimental assessment by GO/KEGG
enrichment and association with t-AML susceptibility.
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ABSTRACT
Copy number variants (CNVs) are currently defined as genomic sequences that are
polymorphic in copy number and range in length from 1,000 to several million base pairs.
Among current array-based CNV detection platforms, long-oligonucleotide arrays promise the
highest resolution. However, the performance of currently available analytical tools suffers
when applied to these data because of the lower signal:noise ratio inherent in oligonucleotidebased hybridization assays. We have developed wuHMM, an algorithm for mapping CNVs
from array comparative genomic hybridization (aCGH) platforms comprised of 385,000 to more
than 3 million probes. wuHMM is unique in that it can utilize sequence divergence information
to reduce the false positive rate (FPR). We apply wuHMM to 385K-aCGH, 2.1M-aCGH, and
3.1M-aCGH experiments comparing the 129X1/SvJ and C57BL/6J inbred mouse genomes.
We assess wuHMM’s performance on the 385K platform by comparison to the higher resolution
platforms and we independently validate 10 CNVs. The method requires no training data and is
robust with respect to changes in algorithm parameters. At a FPR of less than 10%, the
algorithm can detect CNVs with five probes on the 385K platform and three on the 2.1M and
3.1M platforms, resulting in effective resolutions of 24 kb, 2-5 kb, and 1 kb, respectively.
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INTRODUCTION
DNA copy number variation comprises a significant component of total genetic variation in human
(1-4), chimpanzee (5), and mouse (6-9) populations. CNVs have been associated with disease
susceptibility (10-16) and underlie variation in gene expression (17). To date, the genome-wide
discovery of CNVs has been limited to large (>20 kb) events due to technological constraints. In
order to accurately assess the impact of copy number variation on phenotype, as well as to learn
more about their fine structure and origins, we must first be able to reliably detect CNVs of all
sizes and accurately determine their genomic boundaries.

The most common genome-wide approaches to identify CNVs are array-based. These platforms
include bacterial artificial chromosome (BAC) array comparative genomic hybridization (aCGH)
(18,19), long oligonucleotide arrays (20-22) and single nucleotide polymorphism (SNP)
genotyping arrays (23). A critical aspect in selecting a platform for CNV detection is effective
resolution, which we define as the length of the shortest CNV that is detectable at an acceptable
false positive rate (FPR). A number of factors contribute to resolution, including probe density
(i.e., the number of probes that interrogate a region of the genome), probe specificity and
sensitivity. Due to their high probe density, long oligonucleotide arrays theoretically have the
highest resolution and genome coverage of the three platforms (24,25). However, the higher
level of noise of these platforms (24,26) has hampered efforts to mine these data for novel CNVs
using available analytical tools, which were designed for BAC-array analysis. To date, there has
been only one published account of a method designed specifically for detecting CNVs from such
data (27) but there has been no comprehensive analysis of the achievable genome-wide
resolution of these platforms.

The goal of our work was to develop a method for detecting CNVs specifically from long-oligo
aCGH data, characterize its sensitivity, FPR and effective resolution, and compare it to other
CNV detection algorithms. Our focus is the detection of homozygous changes in the inbred
mouse genome. Detection of heterozygous germline changes or somatic changes in mixed
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cellular populations may present additional challenges due to diminished signal intensity.
However, existing computational tools detect even homozygous CNVs with relatively low
sensitivity and unacceptably high false positive rates. Although sequence divergence between a
probe and its target impacts hybridization, no existing CNV detection algorithm has addressed
this problem in the context of oligo-aCGH. Here we show that there is a strong association
between regions of sequence divergence and hybridization signal in high resolution aCGH data
from inbred strains of mice. We present a method that optionally incorporates sequence
information into a Hidden Markov Model (HMM)-based calling algorithm. We assess its sensitivity
and precision, and compare its performance to other algorithms, three of which are commonly
used for lower resolution platforms and one recently developed for dense microarrays.
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MATERIALS AND METHODS
Sample preparation and array comparative genomic hybridization
DNA was extracted from the spleens and kidneys of healthy, young adult (age 8-12 week)
129X1/SvJ and C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME). Different DNA
samples were used for each aCGH platform (385K, 2.1M, and 3.1M). Array comparative
genomic hybridization (aCGH) studies were performed using long oligonucleotide arrays
designed and manufactured by Roche NimbleGen (Madison, WI). The aCGH experiments were
performed using a single array (385K-aCGH) with a median probe spacing of 5.2 Kb (MM6, NCBI
Build 34), a single array (2.1M-aCGH) with a median probe spacing of 1.015 Kb (MM8, NCBI
Build 36) or an 8-array set (3.1M-aCGH) with median probe spacing of 0.49 Kb (MM7, NCBI
Build 35). Labeling, hybridization, washing, and array imaging were performed as previously
described (9,22). All mouse genome coordinates are based on NCBI Build 36 (MM8). Roche
NimbleGen probe coordinates were re-mapped using liftOver (http://genome.ucsc.edu/cgibin/hgLiftOver). Data is available at GEO (http://www.ncbi.nlm.nih.gov/geo/index.cgi) under
accession GSE10511.

Algorithm overview
We developed Washington University HMM (wuHMM) specifically to maximize CNV detection on
high density, long oligonucleotide arrays. wuHMM is comprised of several stages: clustering
log2-ratios, finding regions more likely to contain CNVs, performing local CNV segmentation, and
scoring (Figure 1A). The clustering stage bins log2-ratios for input to the HMM, which facilitates
the incorporation of sequence information. There is an optional stage in which each chromosome
is partitioned according to sequence divergence between the probe and target genomes based
on independently derived genotype data. Segmentation is achieved by first searching for seeds
consisting of short runs of probes with large magnitude log2-ratios. Seeded regions are then
input to an HMM for segment boundary detection and scoring. The HMM (Figure 1B) is
comprised of 5 states that represent normal and abnormal DNA copy number. The model
requires a minimum length of stay in abnormal states in order to prevent singleton outliers from
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being called as CNVs. CNVs are scored based on log2-ratio magnitude, number of probes, and
local noise.

wuHMM can be downloaded from: http://groups.google.com/group/wuhmm. Default parameters
(seed length, number of clusters, and noise penalty) are set to optimized values based on the
sensitivity and FPR of wuHMM applied to data of known copy number. These parameters and
the use of sequence divergence data can be specified by the user.

Sequence divergence
In this optional pre-processing step, partitioning of a chromosome is accomplished by utilizing a
three-state HMM, in which the states represent regions of sequence divergence or similarity
compared to a reference genome, or runs of no genotype calls (Supplementary Figure 1). The
reference is the C57BL/6J inbred mouse genome. The observations in the model are determined
by the genotypes of 138,608 known SNPs (28,29). Specifically, an observation is coded as '0'
when the genotype differs between the test and reference genomes, as a ’1’ when the genotypes
agree, and ‘n’ when there is no call in either strain. This model is appropriate for pair-wise
comparisons between inbred mouse strains containing genomic regions of high pair-wise
polymorphism rates. We required that the system remain within a state for at least five
observations, yielding an average minimum block size of 87 kb, which lies within the estimated
size range of ancestral block sizes in inbred mice (mean: 58 kb, range:1 kb to 3 Mb) (30). The
HMM is trained by expectation maximization.

Clustering
We clustered probes by log2-ratios to achieve two aims. First, clustering facilitated the
normalization of log2-ratios between regions of sequence divergence and similarity. Second,
binning probes by log2-ratios provided a convenient means of linking the decoded states of
probes, as determined by the HMM, to biologically meaningful DNA copy number states (normal,
gain, or loss). The following procedure assigned cluster labels to each probe, ensuring that there
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is the expected number of clusters for input to the HMM:

1. Divide probes in two groups:
Group A: Probes with log2-ratios >= 0
Group B: all other probes
2. Cluster probes in each group into floor(n/2) + 1 groups.
n = number of clusters
3. Merge the cluster in Group A having the minimum magnitude mean log2-ratio and the cluster
in Group B with the minimum magnitude mean log2-ratio into one cluster, resulting in n clusters.
4. Rank clusters by mean log2-ratio.
5. Label each probe by the rank of its cluster.

We used Partitioning Among Medoids (PAM), as implemented in R’s ‘cluster’ package using the
clara function (31). When sequence divergence information is utilized, probes are separated
according to sequence divergence state first, then clustered and labeled as described above
(Supplementary Figure 2). Probe cluster labels are treated as observations by the HMM.

Seeding
It was necessary to target regions of the genome that were likely to contain CNVs prior to
executing a more sensitive CNV-detection algorithm. Without the seeding step we found that
training the HMM on whole chromosomes periodically led to reduced power to detect short CNVs
and misclassification of large regions of chromosomes as CNVs. We identified regions likely to
harbor CNVs by the presence of consecutive probes with large magnitude log2-ratios. This was
achieved using a stringent HMM in which the emissions from abnormal states were restricted to
corresponding clusters. We trained the stringent HMM and performed decoding on each
chromosome separately, producing a set of seeds. A seeded region, which was used as input to
the more sensitive CNV detection algorithm, was defined as the seed-spanning region plus 100
probes on either side. Overlapping seeded regions were merged.
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Hidden Markov Model
Our HMM generally follows the approach to decoding copy number from aCGH data as first
described by Fridyland, et al (32) with several notable exceptions. The true, unobserved DNA
copy number of a given probe is treated as a hidden state and probe cluster labels are the
observed emissions from the model (Figure 1B). The initial emissions of abnormal states are
weighted most heavily to the highest and lowest cluster ranks. Emissions from abnormal states
cannot be from clusters with oppositely signed means. The initial transition probabilities are set
such that most of the chromosome is assumed to be in a normal state. ‘Joiner’ states, which
have an initial emission distribution weighted toward the corresponding abnormal state but permit
emissions from all states, exist in order to prevent CNV call fragmentation. Final emission and
transition probabilities are determined by the Baum and Welch expectation maximization
algorithm for each seeded region until convergence of the model likelihood, which is typically
achieved in fewer than 10 iterations. Training is repeated for each seeded region, varying the
minimum length of stay in an abnormal state from 3 to 10. The model with the greatest likelihood
is then used to determine copy number with the Viterbi decoding algorithm (33). The GHMM
library (http://ghmm.sourceforge.net/software) was used to implement the HMMs.

Scoring function and permutation
We devised a scoring function that uses local noise, number of probes, and log2-ratios to
ascertain the quality of CNV calls. This score, Scnv, is defined as:
Scnv = ln(ncnv) * | median(log2-ratio cnv) | – SD(log2-ratio cnv_nps) * W, where:
n = number of probes comprising the CNV
cnv_nps = index probes within a distance of 5 * length of the call that share the
same sign as the mean(log2-ratio)cnv
W = noise weight term
In attempting to determine the significance of a CNV score, probe locations were randomized for
each chromosome, the segmentation method was applied, and the best score was stored. We
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repeated these steps one hundred times to generate a null distribution of CNV scores for each
chromosome. P-values were computed using R’s ‘quantile’ function, which uses linear
interpolation to estimate the given quantile (34).

Validation
Two methods were used to validate CNV calls. First, we used replicate aCGH experiments at
increasing probe density to identify probes on the 385K array that have reproducible log2-ratio
shifts. This information was used to assess the performance of wuHMM and other CNV detection
algorithms, as described below (see Sensitivity and False Positive Rate). We performed three
replicate aCGH experiments at increasing probe densities: two 2.1M-aCGH (each comprised of a
single 2.1M feature array) experiments and one 3.1M-aCGH (eight-385K arrays) experiment. We
included probes for assessment analysis only if there were at least four probes in the 6 kb
centered at a 385K probe (median inter-probe distance on the 385K array is 6 kb) on both the
2.1M and 3.1M platforms. We termed these ‘informative probes’. The gold standard is the copy
number status (i.e. gain, loss, or neutral) of the informative probes. The copy number status of
an informative probe was defined according to the |mean log2-ratioregion| on the replicate arrays.
Specifically, an informative probe was considered to represent a DNA copy number change if the
|mean log2-ratioregion| > threshold on all replicates, where the threshold varied between arrays and
regions of sequence similarity and divergence. If an informative probe was in a divergent region
and its log2-ratio < 0, then it was considered to represent a DNA copy number change if |mean
log2-ratioregion| > SDdivergent_blocks for all replicate arrays, where SDdivergent_blocks is the standard
deviation of probes in divergent regions. For all other informative probes, the threshold is the
standard deviation of the sequence similar regions. The SD cutoffs for the similar regions were
0.2416, 0.2176 and 0.2200 for the 385K, 2.1M and 3.1M platforms, respectively. SD cutoffs for
the divergent regions were 0.4115, 0.3457 and 0.3142.

Independent validation of 10 CNVs (all deletions) was achieved by attempting to amplify by PCR
regions within CNV boundaries. PCR primers (Supplementary Table 1) were designed to localize
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within a CNV. Amplification reactions contained 10 μl of Jumpstart Ready Mix Taq (Sigma,
http://www.sigmaaldrich.com), 100 ng of each primer, and 10 ng of genomic DNA in a final
volume of 20 μl. Amplifications were performed on a PTC-225 Peltier Thermal Cycler (MJ
Research) at standard conditions for 30 cycles and the product was run on a 2% agarose gel,
stained with ethidium bromide, and visualized on a GelDoc (BioRad).

Sensitivity and False Positive Rate
We calculated sensitivity and FPR of CNV detection algorithms on the 385K platform based on
the gold standard. We calculated the sensitivity of CNV calls as the number of probes
representing a true copy number change within predicted CNVs divided by the total number of
probes representing true copy number changes in the gold standard. We defined the FPR as one
minus the proportion of CNVs that are significantly enriched for probes representing a true copy
number change. The enrichment of a CNV was determined by randomly selecting equally sized
regions of the chromosome and recording the proportion of probes representing true copy
number changes that they contain. We repeated this step one hundred times, generating a null
distribution of enrichment values. We designated an observed call as a true positive if its
enrichment value exceeded 95% of the random enrichment values. We observed that due to
differences in probe design between platforms, some high-scoring calls on the 385K-aCGH were
not sufficiently covered on the higher resolution platforms. Therefore, we excluded calls that
were comprised of fewer than 25% informative probes in any performance analysis for wuHMM
and other segmentation algorithms. Also, singletons and doubleton calls were not considered in
any performance analysis.

Other segmentation algorithms
We applied GLAD (35), CBS (36), and BioHMM (37) to the 385K-aCGH data using
BioConductor’s snapCGH package (38). To reduce the amount of processing time required by
GLAD and DNACopy, we divided each chromosome into blocks of approximately 50 Mb. These
methods do not explicitly define segments as amplified or deleted. Segments were classified as

24

‘abnormal’ if the predicted log2-ratio was greater than 0.35 or less than -0.35. We used BreakPtr
(27) version 1.0.5 downloaded from http://tiling.mbb.yale.edu/BreakPtr/. We trained the data
using known gains and losses in 129X1/SvJ. We used the Finder-Core module with the default
transition probabilities.

Other statistical tests
To test the association between sequence divergence and signal intensity, probes were
partitioned according to sequence divergence state as described. A t-test, using R’s t.test
function not assuming equal variances, was applied to the raw, linear-scale signal intensities of
the129X1/SvJ channel.
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RESULTS
Sequence divergence affects probe hybridization signal
There are long regions of the 129X1/SvJ aCGH data that exhibit a dispersed but pronounced
negative log2-ratio (Figure 2). These regions differ from true deletions, which are comprised
almost entirely of negative log2-ratios. It was previously hypothesized that a similar phenomenon
observed in BAC arrays was a result of decreased hybridization efficiency due to sequence
polymorphism between the test and reference genomes (8). There are regions of classical inbred
mouse genomes that exhibit pair-wise polymorphism rates exceeding 1/400 base pairs, reflecting
divergent subspecies ancestry (30). We tested the hypothesis that the regions of dispersed
negative log2-ratios represent blocks of different ancestry in C57BL/6J versus 129X1/SvJ by
partitioning the 129X1/SvJ genome into blocks of sequence similarity and divergence relative to
the C57BL/6J sequence using approximately 140,000 genotype calls. We found 1,826
sequence-similar blocks and 1,790 sequence-divergent blocks (median length 190 and 262 kb,
respectively). As predicted, the signal intensity of 129X1/SvJ in regions of sequence divergence
is significantly lower than in regions of sequence similarity in all experiments in the majority
(18/19, 17/19, and 13/19, on 385K, 2.1M, and 3.1M arrays, respectively) of autosomes (Table 1).
Similarly, the test channel intensity is lower in divergent blocks of 385K-aCGH data from 18 other
inbred mouse strains, suggesting that the association between blocks of sequence divergence
and aCGH signal is not an idiosyncrasy of a single strain comparison but represents a general
phenomenon (data not shown). In order to determine the impact of sequence divergence on
segmentation algorithms we attempted to validate by PCR five deletions in divergent regions
called by a variety of algorithms on 385K-aCGH data. All five putative deletions failed to validate
(Supplementary Figure 3 and data not shown), indicating that they do not represent true deletions
but are instead artifacts of sequence polymorphism affecting hybridization. This underscores the
importance of incorporating methods to differentiate between CNVs and blocks of high
polymorphism rates in order to reduce the number of false positive segment calls.
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Gold standard
In order to assess the FPR and sensitivity of wuHMM and other segmentation methods we
needed to determine the true copy number state of each assayed region of the 129X1/SvJ
genome. Replication by independent methods (e.g., PCR, qPCR, and FISH) is the accepted
standard by which CNV predictions are considered validated. It would not be practical to use any
of these methods to systematically validate the thousands of predictions made by all algorithms
tested. Instead, we determined the 129X1/SvJ copy number of the 6 kb region spanning each
385K-aCGH probe (approximately equal to the median spacing of the platform) by comparison to
replicate experiments at higher resolutions (two 2.1M-aCGH, one 3.1M-aCGH). We reasoned
that if the signal from a 385K-aCGH probe represents a true copy number change, then the log2ratio shift will be reproducible on higher density platforms with more probes reflecting the
variation. The higher density platforms contain, on average, 5.6 and 8.7 probes per 6 kb window
on the 2.1M and 3.1M platforms, respectively. 336,470 probes on the 385K array are informative
(i.e., there were at least 4 probes in the 6 kb region spanning the probe on both the 2.1M and
3.1M platforms). Of the informative probes, we found that 1,886 represented true copy number
changes since they had reproducible log2-ratio shifts on all three replicate arrays. 1,226
informative probes were singletons (i.e., probes representing a copy number change that are
adjacent to informative probes that do not represent true copy number change). Two hundred
fifty-two probes were doubletons, similarly defined as an adjacent pair of validated probes
surrounded by informative probes not representing true copy number change.

We next asked if it would be feasible to detect singletons or doubletons using only log2-ratio
thresholds. Standard deviation (SD) multipliers were used to identify probes as potential CNVs.
Even when the SD multiplier threshold > 5 was applied, 89% of the called probes were false
positives and less than 5% of the called probes were true positives (Table 2). These results
demonstrate that attempting to detect singletons or doubletons from a single experiment will
result in unsatisfactory sensitivity and FPR. For this reason, we removed singletons and
doubletons from both the gold standard and CNV predictions prior to the calculation of sensitivity
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and FPR. Four hundred and eight probes representing true copy number changes remained after
removing singletons and doubletons.

We calculated the sensitivity and FPR of all CNV detection algorithms based on the 385K gold
standard, which is defined as the copy number status of the informative probes. CNV predictions
were considered correct if they contained a significantly enriched number of informative probes
that represented a true copy number change. The FPR was calculated as one minus the ratio of
the number of correct CNV predictions to the total number of CNV predictions. In this way, the
FPR is presented at a CNV-level. However, the sensitivity could only be calculated at the level of
individual probes because the total number of ‘correct’ CNVs remains unknown in our gold
standard. The sensitivity is calculated as the ratio of the number of informative probes contained
within predicted CNVs that represented a true copy number change to the total number of probes
representing true copy number changes.

Scoring function
It is common practice to prioritize or rank CNV predictions for downstream analysis and
experiments such as validation and evaluation of functional significance. We view this
prioritization in terms of a scoring function that relates aspects of the call (e.g., the amplitude of
deviation from a log2-ratio of 0, the number of probes within a segment) to the quality of the call.
A well-designed scoring function will generate high scores for true positive calls and low scores
for false positive calls. We first asked which choice of threshold acted as a better scoring
function: the number of probes per segment, or the |mean log2-ratio| of the segment. We
calculated the sensitivity and FPR of wuHMM across a range of parameter settings and reported
the maximum sensitivity when the FPR < 15% (Supplementary Table 2 and Supplementary
Figure 4). The |mean log2-ratio| performed poorly (mean sensitivity = 8.5%). The number of
probes per segment threshold performed substantially better (mean sensitivity = 40.6%), but we
speculated that a scoring function that uses both parameters would provide further improvement.
A combined scoring function (see Methods) had the best performance at all parameter settings
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(mean sensitivity = 47.8%).

Next, we hypothesized that we could assign a statistical significance to CNV calls by generating a
null distribution of scores for calls made on randomized data. On a per-chromosome basis, we
randomized probe locations, executed wuHMM and stored the highest score. We repeated this
process 100 times to generate a null distribution of scores. We calculated p-values for each
observed call based on comparison of its score to the null distribution of scores. We found that
the FPR of scores with p-values < 0.01 remained above 47%, indicating that this permutation
approach to determining CNV call quality did not achieve an acceptable FPR. Therefore, the
scoring function can be used to evaluate algorithm performance, but significance thresholds for
the scores must be determined empirically.

Algorithm parameters
An important goal in developing wuHMM was to make it tunable such that changes in initial
parameter settings would have predictable effects on performance and therefore could be
adjusted to meet the needs of each individual analysis. We evaluated the effect on wuHMM’s
sensitivity and FPR of varying: the number of clusters, the minimum number of probes required in
the seeding step (seed length), use of sequence information, and the scoring function noise
penalty. First, we investigated the effect of varying only seed length and the number of clusters.
We expected that increasing the seed length would decrease the overall sensitivity and FPR
because larger values of the seed length would increase the likelihood that the algorithm would
skip regions containing small CNVs. We executed wuHMM using a range of seed lengths and
number of clusters, calculated the sensitivity and FPR at increasing score thresholds, and
generated Receiver Operating Curves (Figure 3). As expected, we found that increasing the
seed length reduced the maximum sensitivity (from 70% to 34%) and the maximum FPR (86% to
35%). The best performance (sensitivity = 53% at FPR < 10%) was achieved when seed length
was 2, although a value of 3 performed nearly as well. There was no clear performance trend
with increasing the number of clusters. The best performance (sensitivity = 50%, FPR < 10%),
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achieved with the number of clusters = 5, was substantially better than other numbers of clusters.
These results demonstrate that seed length can be increased to decrease the maximum FPR at
the expense of a much reduced sensitivity. Further, they show that a combination of seed length
= 2 and number of clusters = 5 produces the optimal performance tradeoff. To determine if
wuHMM would be generally applicable with these parameter settings (i.e., that it is not overtrained) we applied it to previously described data from 19 other inbred strains at the 385K
resolution (9). Of the 72 previously discovered ‘high-confidence’ CNVs, 71 (98.6%) were
detected with wuHMM using identical parameter settings (e.g. seed length = 2, number of
clusters = 5, using sequence divergence information). Additionally, the range of call lengths and
number of calls per genome are consistent with the 129X1/SvJ calls (length range: 9 kb - 4 Mb,
median length = 138 kb, mean length = 460 kb). The calls per genome range from one
(C57BL/6Tac) to 75 (Molf/EiJ), with a mean of 36 +/- 17.

We next analyzed the effect of incorporating sequence divergence on wuHMM’s performance.
We calculated the difference between the sensitivity and FPR of wuHMM with or without
sequence divergence at increasing score thresholds. As predicted, utilizing sequence information
reduced both the FPR and the probe-level sensitivity (Figure 4). These effects were greatest for
calls scoring between 0.8 and 1.4, a score range which includes validated gains and losses. We
next calculated sensitivity and FPR using a range of values for the noise penalty, W, which
decreases the score of calls in regions of greater noise (see Methods). We found that increasing
the noise penalty resulted in equalizing the FPRs between wuHMM with sequence information
and without sequence information. At the same time, the sensitivity did not substantially improve,
demonstrating that the use of a noise penalty with sequence divergence information results in
worse overall performance.

Genotype information is not readily available for all aCGH experiments that may contain noise
due to sequence divergence. We asked if using a noise penalty would improve FPR at an
acceptable loss of sensitivity when sequence information is not available. We executed wuHMM
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without sequence information using a range of penalty values and calculated the sensitivity and
FPR at increasing score thresholds (Supplementary Figure 5). We found that there was no
performance improvement when using any non-zero penalty. We concluded that for the range of
values tested, the noise penalty does not enable the score function to differentiate between real
calls and noise. Therefore, we recommend the use of conservative score thresholds when there
is substantial noise in the data.

Effective resolution
Using parameter values that optimized sensitivity and FPR (seed length = 2, number of clusters =
5, noise penalty = 0) we applied wuHMM to all data sets. We selected a score threshold that
yielded a FPR < 7% and sensitivity of 56% on the 385K platform. We attempted to independently
validate ten calls made from the 2.1M and 3.1M experiments by PCR. We considered a call to be
validated when we were able to detect an amplified product in the C57BL/6J sample but not in the
129X1/SvJ sample. All ten calls confirmed the wuHMM predictions, independently demonstrating
that wuHMM can reliably detect calls comprised of as few as three probes on 2.1M-aCGH and
seven probes on 3.1M-aCGH (Figure 5).

We estimated the effective resolution of the 385K platform by determining the length of the call
with the fewest probes with a score exceeding 1.9 (i.e. at a FPR < 7%) (Table 3). Assuming that
the relationship between CNV score and the FPR remains relatively constant across aCGH
densities, we estimated the effective resolutions of the 2.1M and 3.1M platforms by averaging the
lengths of the calls comprised of the fewest probes with scores exceeding 1.9 (Table 3).

Comparison to other methods
We compared the performance of our approach to four other segmentation algorithms: Gain and
Loss Analysis of DNA (GLAD), BioHMM, DNACopy, and BreakPtr. The performances of GLAD
and DNACopy, as well as other HMM implementations have been compared previously using
well-characterized BAC array and simulated data (39,40). Using default parameters, we applied
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each algorithm to the 385K-aCGH data, scored CNV calls, removed singletons, doubletons, and
calls comprised of less than 25% informative probes (see Methods), and computed sensitivity and
FPR based on the gold standard. In order to ensure an unbiased comparison of algorithms, we
determined the lowest score cutoff at which each method reached a FPR < 10%. For all methods
this score threshold was 1.9. wuHMM reached the highest sensitivity, followed closely by
DNACopy and more distantly by BreakPtr and GLAD (Table 4). All HMM-based methods
required less than an hour of execution time. Although input data was partitioned prior to input to
DNACopy and GLAD, these methods still had the longest executions times at 1.4 and 12.4 hours,
respectively. BreakPtr appeared to be critically dependent on its training set. We initially trained
the ‘no-change’ state with data from a self-self hybridization, but this resulted in BreakPtr calling
over 10% of the informative probes, resulting in a 99% FPR. Among currently available methods,
wuHMM achieves the highest sensitivity while maintaining an acceptable FPR.
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DISCUSSION
Prior to this report, the selection of tools for the analysis of long oligonucleotide aCGH data was
limited largely to software originally designed for other aCGH platforms, such as BAC-based or
SNP genotyping arrays. We developed wuHMM to improve CNV detection from long
oligonucleotide aCGH data that may be confounded by sequence divergence. wuHMM
addresses sequence divergence by increasing the call stringency in sequence divergent regions
of the genome. The effect of this strategy is to lower the FPR and, to a lesser extent, the
sensitivity. In order to assess the algorithm, we developed a validated data set that should be a
useful resource for the evaluation of other segmentation methods. By applying wuHMM to the
validated data set, we demonstrated that it reaches the highest sensitivity among currently
available methods at a FPR of less than 10%.

There are two caveats that apply to this analysis. First, in the current version of wuHMM,
sequence divergent regions were estimated using only 140,000 SNPs. Therefore, small regions
of sequence divergence may be missed. When more sequence data becomes available it can be
incorporated into our method to better define the divergent regions, perhaps even down to the
single aCGH probe level. Second, we expect that all existing CNV detection algorithms will
exhibit reduced sensitivity when applied to aCGH data from outbred populations or samples with
mixtures of somatic and germline copy number changes.

We estimate that effective resolutions of the 2.1M and 3.1M probe aCGH platforms, extrapolated
based on a score threshold that yielded a FPR < 10% on the 385K probe platform, are 2-5 kb and
1 kb, respectively. However, although we independently validated several CNVs shorter than 5
kb, the overall confidence in resolution estimates for the 2.1M and 3.1M probe arrays will require
additional evaluation. The first genome-wide studies of normal copy number variation in the
mouse genome, based on BAC-aCGH platforms, were limited to a resolution of approximately 1
Mb (6-8). In 385K-aCGH data sets using a single whole-genome array (median probe spacing of
5.2 kb) and CNV analysis algorithms available at the time, we previously reported a total of five
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CNVs in the 129X1/SvJ genome (9). Applying wuHMM to the 385K-aCGH data, we can now
detect 15 CNVs in the 129X1/SvJ genome at an empirical FPR < 10%. Applying wuHMM to
3.1M-aCGH (an 8-fold increase in resolution) yields 167 CNVs. Theoretically, another 10-fold
increase in probe density to a median probe spacing of approximately 87 bases for the mouse
genome will enable the resolution of ‘sub-CNV’ events (i.e. insertion-deletions). Comprehensive
tools such as the ones presented here are necessary to accurately assess the phenotypic impact
of CNVs, improve our understanding of CNV origins, and facilitate integrated quantitative trait
locus (QTL) mapping, linkage, and association studies.
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Table 1. Relationship between sequence identity and aCGH signal.
385K-aCGH
Probe count
Chr

M

MM

2.1M-aCGH

Test signal
M

MM

p-value

Probe count
M

MM

3.1M-aCGH

Test signal
M

MM

p-value

Probe count
M

MM

Test signal
M

MM

p-value
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1

13,188

16,205 4655 4489 8.90E-15

72,049

91,734 3550 3331 1.56E-82

101,963

124,620 3266 3120 2.60E-44

2

13,909

13,990 4612 4455 1.30E-12

76,513

77,565 3516 3463 5.04E-06

111,127

114,313 2999 2854 2.80E-48

3

11,306

11,954 4682 4485 7.70E-16

64,400

67,515 3427 3316 9.24E-20

85,703

90,427 2494 2422 2.00E-12

4

8,747

13,700 4628 4434 4.00E-15

48,344

78,238 3612 3351 3.07E-81

72,101

111,243 2508 2427 4.50E-16

5

9,935

12,574 4646 4505 1.20E-07

55,891

69,525 3601 3497 2.35E-14

79,773

102,559 2703 2629 1.70E-15

6

12,095

10,437 4661 4414 1.60E-27

67,247

57,338 3205 3113 1.49E-14

94,546

82,567 2865 2772 3.20E-19

7

8,542

11,126 4626 4359 8.40E-21

48,250

63,624 3334 3029 6.48E-116

74,732

93,915 3606 3450 1.60E-21

8

7,962

11,620 4662 4379 2.40E-23

43,465

65,059 3303 2986 3.81E-124

65,419

94,888 3646 3422 1.20E-39

9

7,903

11,389 4617 4422 2.20E-14

43,317

62,739 3295 3137 9.58E-32

65,014

94,193 2385 2095 7.00E-149

10

13,865

5,569 4670 4562 2.10E-04

77,515

32,036 3139 3183 1.49E-03

106,880

43,868 2011 2000 2.60E-01

11

11,058

8,255 4567 4438 5.40E-06

62,019

44,518 3311 3210 3.13E-13

95,181

69,851 2445 2453 5.00E-01

12

8,686

7,689 4660 4417 1.60E-17

50,261

43,365 3057 2972 6.60E-10

69,487

61,473 3193 3220 1.60E-01

13

9,250

8,121 4671 4507 2.60E-08

51,745

45,216 3062 2916 7.69E-28

75,538

63,704 3269 3193 8.30E-06

14

7,982

9,259 4682 4389 4.90E-23

46,043

51,318 2918 2820 2.87E-13

60,075

73,647 2674 2683 5.10E-01

15

7,888

7,931 4637 4388 4.60E-16

43,200

43,898 3073 2814 1.34E-71

63,517

62,254 2512 2365 1.90E-42

16

7,768

6,861 4616 4563 7.70E-02

44,036

37,931 2967 2856 4.09E-15

60,921

51,324 2474 2465 4.20E-01

17

5,464

8,188 4642 4486 1.10E-05

30,042

46,894 3025 2958 1.72E-05

42,824

67,144 2851 2708 1.80E-23

18

6,324

7,615 4707 4538 4.80E-08

34,739

41,374 2999 2980 1.93E-01

48,748

60,966 3124 3053 9.70E-07

19
7,336
1,773 4645 4490 1.10E-03
40,292
9,748 3111 3008 2.57E-05
60,703
14,985 3078 3055 3.20E-01
MM: Regions of high polymorphism between C57BL/6J and 129X1/SvJ (“mismatched”); M: Non-polymorphic regions (“matched”). Probe count
columns contain the number of probes within M and MM regions. Test signal columns contain the mean, single channel, linear-scale aCGH
intensities of the M and MM regions. The p-value is the result of a t-test, testing the difference of the mean signals of M and MM probes.

Table 2. Detection of singletons and doubletons on 385K-aCGH.
SD
multiplier

Singleton
Sensitivity

Doubleton
Sensitivity

0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
2.25
2.50
2.75
3.00
3.25
3.50
3.75
4.00
4.25
4.50
4.75
5.00
5.25
5.50
5.75
6.00

0.869
0.742
0.631
0.553
0.487
0.431
0.376
0.336
0.300
0.259
0.234
0.206
0.177
0.152
0.127
0.108
0.090
0.074
0.064
0.048
0.037
0.031
0.024
0.020

0.881
0.782
0.698
0.631
0.560
0.496
0.425
0.381
0.329
0.298
0.282
0.214
0.183
0.159
0.139
0.115
0.091
0.079
0.052
0.040
0.036
0.016
0.012
0.008

FPR
0.993
0.992
0.989
0.985
0.979
0.971
0.963
0.953
0.942
0.933
0.923
0.916
0.910
0.905
0.902
0.896
0.894
0.888
0.885
0.891
0.897
0.898
0.899
0.903

38

Number of probes
(percent of total)
251166 (74.6)
176851 (52.6)
118501 (35.2)
77423 (23)
50327 (15)
33049 (9.8)
22172 (6.6)
15630 (4.6)
11409 (3.4)
8594 (2.6)
6698 (2)
5270 (1.6)
4226 (1.3)
3384 (1)
2718 (0.8)
2200 (0.7)
1786 (0.5)
1415 (0.4)
1109 (0.3)
906 (0.3)
735 (0.2)
598 (0.2)
467 (0.1)
393 (0.1)

Table 3. Effective resolution of aCGH platforms analyzed by wuHMM.
Platform

Resolution
(kilobases)

Standard
deviation

Segment Length
(base pairs)

Minimum
Median
23.7
0.2629
23,577 191,594
385K
5.2
0.3336
1,872
7,618
2.1M-a1
2.2
0.2846
1,906
7,067
2.1M-b2
1.1
0.2690
909
6,156
3.1M
1
First technical replicate. 2Second technical replicate.
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Segment Length
(probes)
Minimum
5
3
3
3

Median
23
7
7
9

Table 4. Performance of segmentation algorithms on 385KaCGH data
Method

Probe
sensitivity

Execution time
(hours)

wuHMM

56.1

0.17

Genotype data

DNACopy

54.4

1.4

Partition input

BreakPtr

43.9

0.02

Supervised
training

GLAD

43.1

12.4

Partition input

BioHMM

21.6

0.1

Additional input

None
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Figure 1. (A) Flow diagram of the wuHMM algorithm. Dashed processes are optional
and are executed when the sequence divergence information is utilized. Processes in
gray are repeated on permuted probe locations to generate null score distributions for
each chromosome. (B) Hidden Markov Model. ‘Norm’, ‘Gain, and ‘Loss’ indicate states
representing normal, increased, and reduced DNA copy number, respectively. Not
shown, but implemented, are multiple states per abnormal state that enforce a minimum
number of probes per abnormal state. This minimum is automatically selected for each
seeded region as described in Methods. Transitions are permitted between normal,
increased, and reduced states. A ‘Join’ state can transition to itself or back to the
corresponding abnormal state.
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Figure 2. 3.1M-aCGH log2-ratio plot of 129X1/SvJ chromosome 7. Blocks of sequence
divergence are shown in red. Blocks of divergence correspond to aCGH probes with
lower log2-ratios and can potentially confound CNV calling algorithms.
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Figure 3. Receiver Operating Curves characterize the performance of wuHMM. (A)
Each curve represents the performance of wuHMM at a given minimum seed length.
Score cutoffs ranging from 0 to 2.5 were used to calculate sensitivities and false positive
rates averaged across executions of wuHMM with different numbers of clusters. Circles
represent score cutoffs of 0.0, 0.5, 1.0, 1.5, and 2.0, from right to left. The vertical
dashed line represents a FPR = 10%. (B) The performance of wuHMM varying the
number of clusters in the clustering stage. Score cutoffs ranging from 0 to 2.5 were
used to calculate sensitivities and false positive rates averaged across executions of
wuHMM with different seed lengths. As in (A), circles represent score cutoffs of 0.0 ,0.5,
1.0, 1.5, and 2.0, from right to left, and the vertical dashed line represents a FPR = 10%.
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Figure 4. Performance differences between wuHMM with sequence divergence and
without sequence divergence. (A) FPR difference. Y-axis is the difference between the
average false positive rates at the given score cutoff. A value below the y=0 line
represents an improvement in the FPR when sequence divergence is utilized. (B)
Sensitivity difference. Y-axis is the difference between the average sensitivities at the
given score cutoff. In (A) and (B) each curve represents the performance difference with
varying noise penalties (W). FPRs and sensitivities are averaged across a range of
values for the number of clusters and minimum seed length.
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Figure 5. Validation of selected 3.1M-aCGH CNV calls in 129X1/SvJ. (A) Log2-ratio
plots of validated 3.1M-aCGH CNV calls. The genomic position is plotted on the x-axis
and the log2 (129X1/SvJ signal / C57BL/6J signal) is plotted on the y-axis. CNVs are
annotated with a unique identifier (Seg ID), boundaries, mean log2-ratio, and score.
Dotted lines indicate CNV boundaries as determined by wuHMM. (B) PCR validation.
All ten deletions were validated by PCR, as demonstrated by a visible product using
C57BL/6J, but not 129X1/SvJ genomic DNA. The marker is a 100 bp ladder. A region
not deleted in 129X1/SvJ serves as a positive control.
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Supplementary Figure 1. Genome partitioning by sequence divergence as
determined using SNP genotype calls. (A) An HMM for determining regions of
sequence divergence (Div) or similarity (Sim), compared to a reference genome, or
runs of no genotype calls (No call). (B) Example of a transition from a similar (grey) to
a divergent (tan) sequence block based on SNP genotype calls.
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Supplementary Figure 2. Ranking probes by cluster. After probes are divided
according to sequence divergence, log2-ratios are separately clustered using PAM.
Clusters are ranked by mean log2-ratio and probes are assigned their respective
cluster rank. The goal of clustering probes separately is to normalize signals across
regions of sequence divergence. Probes are colored by their cluster rank. Note that in
regions of sequence divergence (indicated by red blocks) a larger magnitude log2-ratio
is required for a probe to be included in extreme clusters.
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Supplementary Figure 3
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Supplementary Figure 3. (A) Log2-ratio plots of the invalidated calls. Red blocks
indicate blocks of sequence divergence. Seg ID 3548 was only called by wuHMM
when sequence divergence information was not used. (B) PCR validation of two
putative deletions called by several segmentation algorithms. For each call, primer
pairs for two non-overlapping amplicons were designed. Primer pair IDs are displayed
and sequences are available in Supplementary Table 1. In both cases, the putative
CNV is invalidated. NT, no template.
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Supplementary Figure 4. Comparison of threshold criteria. Different criteria were
applied to predictions made with wuHMM at optimal algorithm parameters (seed length
= 2, clusters = 5, using sequence divergence information). (A) FPR (top) and
sensitivity (bottom) of a threshold using only log2-ratio amplitude, (B) only number of
probes, and (C) score function.
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Supplementary Figure 5. Noise penalty performance comparison of wuHMM without
using sequence information for score penalties ranging from 0 to 4. (A) The sensitivity
of calls made at increasing score cutoffs. (B) The FPR of calls made at increasing
score cutoffs.
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ABSTRACT
The extent to which differences in germ line DNA copy number contribute to natural phenotypic
variation is unknown. We analyzed the copy number content of the mouse genome to a sub-10
kb resolution. We identified over 1,300 copy number variant regions (CNVRs), most of which
are < 10 kb in length, are found in more than one strain, and, in total, span 3.2% (85 Mb) of the
genome. To assess the potential functional impact of copy number variation, we mapped
expression profiles of purified hematopoietic stem/progenitor cells, adipose tissue and
hypothalamus to CNVRs in cis. Of the more than 600 significant associations between CNVRs
and expression profiles, most map to CNVRs outside of the transcribed regions of genes. In
hematopoietic stem/progenitor cells, up to 28% of strain-dependent expression variation is
associated with copy number variation, supporting the role of germ line CNVs as major
contributors to natural phenotypic variation in the laboratory mouse.
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INTRODUCTION
Copy number variants (CNVs), currently defined as genomic sequences greater than one
kilobase that are polymorphic in copy number, have been identified in diverse species including
human, chimp, rat, mouse, and drosophila1-10. In the short interval since the discovery of widespread copy number variation in apparently healthy individuals, there has been rapid expansion
of both CNV detection techniques and their application across a range of biological samples and
species. From these studies, it is apparent that copy number variation exceeds single nucleotide
polymorphisms (SNPs) as a source of genetic variation, and that many CNVs contain or overlap
genes and, thereby, may have functional effects. However, the role of copy number variation in
mediating both ‘normal’ phenotypic variation and disease susceptibility is only beginning to
emerge11-14.
Fundamental questions about the nature and impact of CNVs remain unanswered,
mainly due to methodological constraints. We set out to determine the copy number variable
content of the mouse genome and estimate its functional impact, as measured by gene
expression profiling in vivo. The inbred mouse is an ideal model organism for this study for
several reasons, including its homozygous genome, the ease with which biological samples can
be acquired, and the preeminent role of the mouse as a model for biomedically relevant traits
and diseases. Gene expression variation is a trait amenable to genetic mapping because it is
easily quantified in vivo, it is the phenotype most proximally related to genetics, and the
expression of all genes can be measured simultaneously. Finally, it is reasonable to
hypothesize that the effect size of structural variations on gene expression will be large, so that a
genome-wide association study could be informative, even with modest sample sizes.
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RESULTS
CNV detection, genotyping, and validation
To map the CNV content of the mouse genome, we selected 17 Tier 1-3 Mouse
Phenome Project strains15 and three additional strains of biomedical interest (LG/J, NZB/BINJ,
129X1/SvJ), representing all major inbred lineages. We performed comparative genomic
hybridization using a long-oligonucleotide array containing 2,149,887 probes evenly spaced
across the reference genome with a median inter-probe spacing of 1,015 bases. We performed
segmentation using wuHMM, a Hidden Markov Model algorithm that utilizes sequence-level
information and can detect CNVs less than 5 kb in length (fewer than five probes) at a low false
positive rate16. wuHMM scores CNVs based on the number and median log2-ratio of the probes
comprising the prediction, such that calls with higher scores are more likely to represent true
events. CNVs called in different strains that overlap can be assigned different boundaries due to
technical or biological sources of variability. Because fine-mapping all putative CNVs is not
feasible at present, a common approach to handling complexity and ambiguity in CNV
boundaries is to treat overlapping CNVs as a unit, or, copy number variable region (CNVR)4.
We merged overlapping wuHMM calls into CNVRs, some of which have complex architectures
(Figure 1). We refer to CNVRs as ‘complex’ or ‘simple,’ as determined by wuHMM boundary
concordance across strains (see Methods). To assign CNVR genotype calls to strains for QTL
mapping and to improve upon the sensitivity of wuHMM, we clustered the log2-ratios of each
CNVR (see Methods). The number of genotypes per CNVR was determined by selecting the
cluster number that maximized the average silhouette function, which is a measure of clustering
quality17. Genotypes were assigned according to the clusters in which strains were grouped.
We refer to genotypes that differ from the reference strain’s genotype as ‘abnormal’ in complex
CNVRs, and as ‘gain’ or ‘loss’ in simple CNVRs if the mean log2-ratio is greater or less than the
reference sample, respectively.
Using initial parameters, wuHMM identified 10,681 putative CNVs which were merged
into 3,359 CNVRs. To determine the false positive rate (FPR) of our CNV predictions, we
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randomly selected 61 short CNVRs for independent validation by qualitative (for losses) or
quantitative (for gains) PCR (qPCR). The FPR approached 0 for CNVRs with average scores
exceeding 1.5 and 2.5 for gains and losses, respectively (Supplementary Table 1). Therefore,
we selected these score thresholds, resulting in an empirically estimated individual strain CNVR
genotype FPR < 4.0%. For complex CNVRs, the same threshold was applied if the region
contained either wuHMM gains or losses exceeding the corresponding threshold. We called the
1,333 CNVRs that passed these thresholds ‘high-confidence’ CNVRs and retained them for
further analysis and quantitative trait mapping (Supplementary Figure 1, available at
http://graubertlab.dom.wustl.edu/downloads.html, and Supplementary Table 2).

Copy number variation in the inbred mouse genome
The 1,333 high-confidence CNVRs span 85 million non-redundant bases (3% of the
genome) and are distributed across all 19 autosomes and the X chromosome (Figure 2). The
CNVRs range in length from 1,871 bases to 3.84 Mb (mean length is 64 kb, median is 9 kb, over
50% are less than 10 kb) (Figure 3A). Although the length distribution of CNVRs is highly rightskewed, confirming previous estimates derived from CNVR mapping studies performed with
lower resolution platforms18 and paired-end mapping19, the overall contribution of small CNVRs
(i.e., less than 10 kb) to the total copy number variable content of the genome makes up only 3.3
Mb (0.13%) (Figure 3B), a finding consistent across all strains (Supplementary Figure 2).
Complex CNVRs make up 23% of all CNVRs, but 63% of the CNV sequence content. The
majority of small CNVRs are exclusively genotyped as losses (82%), probably reflecting the
increased power to detect homozygous losses versus integral gains with a small number of
aCGH probes. We detected a total of 663 gains, 2,854 losses, and 2,772 abnormal CNVR
genotypes. 67% of CNVRs were called as gain, loss, or abnormal in more than one strain. The
number of CNVR gains, losses, or abnormal genotypes ranges from 215 (C58/J) to 413 (KK/HIJ)
per strain (mean = 331). The total CNV sequence per strain ranges from 26.4 (C58/J) to 48.3
(NOD/ShiLtJ) Mb (mean = 39.1 Mb); no single strain contributed disproportionately to the CNVR
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map (Figure 3C and Supplementary Figure 2).
Several previous reports have investigated the extent of copy number variation in inbred
strains of mice1,2,5,20,21. If de novo events contribute only minimally to copy number variation
among individuals within a strain22,23, then as detection technologies improve, studies assaying
the same strains will have increasingly concordant results. We compared our CNVR map to
previous reports that also used high-density oligonucleotide aCGH (see Methods). We found
that when we compared CNVRs defined using strains in common with other studies, our map
largely recapitulated the CNVRs found in the other studies: 64-84% of CNV content in the other
studies was also detected in our high-confidence CNVRs (Supplementary Table 3). 48-87% of
the copy number variable content that we report in the 19 strains is novel. However, when we
compared CNVR maps regardless of strain we found that only 16% of the copy number variable
content in our map was novel, suggesting that much of the total copy number variable sequence
of the reference genome is known at the presently available detection limit.
Non-allelic homologous recombination (NAHR) has been proposed as a mechanism of
CNV formation24. The hypothesis that segmental duplications (sequences >1 kb and having >
90% similarity to at least one other genomic region) act as nurseries of CNV by promoting NAHR
has been supported by the enrichment of segmental duplications within and around CNVRs20,25.
By permutation testing (see Methods), we found that there is significantly more segmental
duplication sequence within and directly bordering medium (10-100 kb) and large (>100 kb)
CNVRs (fold = 3.0 and 12.9, respectively, P < 0.01), but that segmental duplications are found
less often than expected by chance within and near small (<10 kb) CNVRs (fold = 0.37, P <
0.01) (Figure 4 and Supplementary Table 4), consistent with a prior report of stronger
association between segmental duplications and long CNVRs4. The pattern of enrichment of
segmental duplication sequences near medium and large CNVRs extends to 2 Mb beyond the
CNVR boundaries (fold from 2.25 - 1.43 and 7.80 - 2.45, respectively, P < 0.01) as does the
pattern of depletion around small CNVRs (fold = 0.27 - 0.75, respectively, P < 0.01). Like
segmental duplications, it has been suggested that repetitive elements may facilitate CNV
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generation through NAHR. Indirect evidence supporting this hypothesis has been presented in
inbred mice where LINEs are enriched within segmental duplications20. We found that LINEs
are enriched within medium and large CNVRs (fold = 1.61 and 1.50, P < 0.01), but are not
enriched in small CNVRs (fold = 0.95, P = 0.81). We found an enrichment of LINE elements in
sequences flanking all CNVRs types, although the association is less for small CNVRs (fold =
1.14 for small, 1.51 for medium, 1.43 for large, P< 0.01). Therefore, it is unlikely that small
CNVRs are variations in the copy number of repetitive elements themselves26, but rather LINEs
may facilitate the removal or expansion of neighboring sequence. Long terminal repeats (LTRs)
are enriched within all CNVRs (fold = 1.3, 1.4, 1.53, P<0.01). This association persists for
regions surrounding CNVRs to at least 10 kb for medium and large, but not small CNVRs.
SINEs are depleted within and surrounding medium and large, but not small CNVRs (fold = 0.7,
0.45, P<0.01). Taken together, this analysis confirms that CNVRs greater than 10 kb frequently
contain or directly border highly homologous elements of the genome that can facilitate NAHR
and therefore CNVR generation. But, with the exception of the weak association between the
regions surrounding small CNVRs and LINE sequences, there is no apparent genomic feature
that could facilitate NAHR and give rise to the abundant, small, high-confidence CNVRs.
Therefore, their origins will require detailed genomic analysis and further exploration.
We next determined the gene content of the high-confidence CNVRs, finding that 432
high-confidence CNVRs contain or partially contain 679 genes. Previous CNVR studies of the
mouse genome have shown that CNVRs overlap coding sequence no more often than expected
by chance, in contrast to CNVRs in human and rat genomes which appear to be enriched for
gene content1,4,8,21. With a more comprehensive and finer-resolution map, we retested this
hypothesis by permutation analysis. We found that small, medium and large CNVRs are found
in genic regions less frequently than expected by chance (fold=0.86, 0.71, 0.90 respectively,
P<0.01, 0.01, 0.05) (Figure 4).
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Expression profiling
To estimate the overall impact of CNV on gene expression in vivo, we first performed
expression profiling of hematopoietic stem/progenitors cells using the Illumina Mouse Beadchip6v1 platform (see Methods). Among many cell types and tissues suitable for this study we
chose to profile a population that has well-defined surface markers, enabling the enrichment of a
highly purified cell population that is transcriptionally active27, increasing the number of genes
that could be assessed for association with CNVRs. We pooled bone marrow cells from two
individuals from each strain and analyzed 2-3 biological replicates per strain (46 expression
experiments). 29% of the probes on the array were detected as ‘present’ in at least three strains
(see Methods). To validate the sort purity, we examined the expression profiles of the cell
surface markers utilized in the sort strategy and found that they were consistent with the
immunophenotype of the post-sort products (Supplementary Figure 3).
To determine the extent to which expression variation is associated with copy number
variation, we first identified the genes that exhibit strain-specific expression. We identified 1,469
probes with significantly higher between- versus within-strain expression differences (P < 0.01,
see Methods). We also determined the strain-specific expression profiles in epididymal adipose
tissue and hypothalamus, as those data sets were publicly available28,29. We removed
expression data for strains that were not profiled in our CNVR mapping work, leaving 15 strains
from each study. Since no strain replicates were available in these studies, we identified strainspecific probes as those with a ratio of maximum to minimum expression > 3, the same
threshold used to identify ‘variable’ expression traits in those studies (Table 1). It is impossible to
determine if the differences in the number of ‘Present’ and strain-specific expression traits
between tissues is due to fundamental differences in cross-tissue expression variation or, more
likely, to the significant differences in the expression profiling platforms and analysis methods
utilized in these studies.
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Expression quantitative trait mapping
CNVRs may impact local gene expression through a variety of mechanisms, including
gene dosage, removal or relocation of regulatory material, or ‘neighborhood effects’ that disrupt
local chromatin structure30. We estimated the overall contribution of CNVRs on local expression
by in silico eQTL mapping, in which gene expression profiles were treated as quantitative traits
and CNVRs as genetic markers. We limited the analysis to CNVR-expression traits that are
tightly linked (< 2 Mb apart) because of reduced power to detect trans effects with a small
sample size. We calculated eQTL significance using a weighted permutation method that
accounts for the complex ancestral relationship among inbred strains31,32, and controlled the
family-wise error rate arising from testing the association between a trait and multiple CNVRs by
applying the Holm multiple testing correction to each trait’s p-values separately33.
We identified 672 significant associations between strain-specific expression traits and
CNVRs in the hematopoietic stem/progenitor compartment. Because we used an alpha
threshold of 0.05, after correcting for multiple tests we would expect to find only 113 associations
by chance. The number of traits associated with a CNVR (degree of pleiotropy) ranged from 118 (mean=2.47, median=2); the number of CNVRs associated with a trait ranged from 1-9
(mean=1.65, median=1). While there were more eQTLs in which the Illumina probe sequence
overlapped the CNVR than expected by chance (P < 0.05 by Fisher’s Exact Test), most eQTLs
(92.3%) map outside of the corresponding CNVR. If these intergenic CNVRs mediate
expression variation, they do so via mechanisms other than changes in gene dosage. CNVRs
of each categorization, either by size or complexity, were found to be eQTLs and each was as
likely to be an eQTL as expected by chance. After selecting the most significant association per
trait from the 672 eQTLs, we found that 408 strain-specific expression traits representing 391
genes (27.8% of 1,469 strain-specific traits) were associated with 214 CNVRs (16% of all 1,333
CNVRs and 44.2% of the 484 testable CNVRs) (Table 1 and Supplementary Table 5). The
frequency of eQTLs dropped with increasing distance from CNVR boundaries to expression
probe locations (proximity) (Supplementary Figure 4). Similarly, the fraction of expression
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variation explained by a trait’s association with a CNVR decreased significantly with proximity
(Supplementary Figure 4)
To validate the KL eQTLs, we queried the expression profiles of the 391 eQTLassociated genes in Kit+/Lineage-/Sca1+ (KLS) hematopoietic stem cells purified from BXD
recombinant inbred mice34. Because the BXD mice are homozygous for either the C57BL/6J or
DBA/2J genotype at most loci and SNP genotype data is publicly available, we were able to
assign an inferred CNVR genotype based on the parental strain of origin of the SNP markers
spanning each CNVR (Supplementary Table 6). Of the 160 KL eQTL-associated genes that
were unambiguously annotated with a gene symbol, 74 genes (93 probe sets) were present on
the Affymetrix U74A expression platform and 31 were detected as expressed in >80% of the RI
lines. We found that 29% of these testable eQTL-associated genes had expression profiles that
were also associated with the inferred CNVR genotype in the KLS BXD data (P-value < 0.05)
(Supplementary Table 7).
Smaller proportions of strain-specific expression variation were associated with CNVRs
in the other two tissues that we were able to analyze: 181 of 4,083 (4.4%) and 78 of 2,879
(2.7%) strain-specific traits in adipose tissue and hypothalamus, respectively, after selecting the
most significant associations per trait (Table 1). Similarly, fewer CNVRs were detected as
eQTLs: 24.9% and 15.0% of testable CNVRs in adipose tissue and hypothalamus, respectively.
While there is variability in the impact of CNV on expression variation between tissues,
differences in the number of eQTLs we detected in adipose tissue and hypothalamus cells are
likely due to the reduced power (25% fewer samples) and less robust methods used to identify
strain-specific expression in these data. The relationships between eQTL frequency and
proximity, and between eQTL effect size and proximity, were present to a lesser extent in
adipose and were not present in the hypothalamus (Supplementary Figure 4). As we found in
the hematopoietic compartment, few adipose and hypothalamus eQTLs overlapped their
associated traits (6.0% and 6.4%, respectively), but this was more than expected by chance
(P<1e-5 and P<0.01 in adipose and hypothalamus, respectively). CNVRs across all length and
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complexity ranges were observed as eQTLs; no categorization was enriched or depleted.
Next, we asked whether any eQTLs were shared across tissues. Because we utilized
expression data from different platforms, we defined expression trait overlap at the level of gene
annotation rather than probe sequence. We found twenty-three eQTLs present in more than
one tissue, five of which were gene-dosage effects (Figure 5 and Table 2). A correlation
between Alad gene dosage, mRNA abundance, and enzymatic activity was previously
demonstrated35,36 and Alad expression variation was associated with a cis-eQTL reported in an
F2 inter-cross37, demonstrating that our analysis was able to detect known gene dosage eQTLs.
Further, we found that strain-specific Glo1 over-expression is due to a large gain and that this
gene-dosage effect is consistent across all three tissues that we tested (Figure 6A). A strainspecific expression pattern of Glo1 in hypothalamus was previously shown to be associated with
and potentially casual for anxiety-related behavior38. Our analysis is the first, to our knowledge,
to show that this expression variation is due to a CNV. Most eQTLs are found in only one tissue,
indicating that tissue-specific factors compensate for CNVR-mediated gene expression variation.
For example, the expression of guanylate-binding protein 1 (Gbp1) is associated with a CNVR
containing its 3’-exon and 3’-UTR in hematopoietic and adipose cells, but not hypothalamus
(Figure 6B). The expression pattern of Gbp1 (highly expressed in both hematopoietic
stem/progenitor cells and adipose tissue in strains that contain the CNV, but not expressed at
detectable levels in strains without the CNV or in the hypothalamus regardless of CNV
genotype) is consistent with a model of expression regulation where hypothalamus-specific
down-regulation or alterative splicing of Gbp1 overcomes the CNVR effect apparent in other
tissues.
We reasoned that CNVRs that mediate expression variation by large scale disruption or
modification of local chromatin structure rather than by gene dosage were likely to impact the
expression of more than one gene. We tested one implication of this hypothesis using random
permutations of the hematopoietic eQTL data. We calculated the probabilities of finding the
observed number of CNVRs with a given degree of pleiotropy (defined as the number of

75

expression traits associated with a CNVR). We found that there were more CNVRs with 7 and 8
associated expression traits than expected by chance (P < 0.05, 10,000 permutations). One
CNVR (CNVR-ID 3014) with seven associated traits is a deletion located approximately 100 kb
from the Major histocompatibility (Mhc) locus on chromosome 17 that removes highly conserved
sequence with predicted regulatory potential. All of the associated traits are Mhc class Ib genes,
many of which are expressed in multiple tissues and have unknown specific functions39. Genes
at this locus have been speculated to undergo distal regulation via a chromosomal looping
mechanism40 and, therefore, copy number changes that modify this looping structure would be
expected to have pleiotropic effects on local expression. Alternatively, because the H2-T locus
is known to have strain-specific duplications39, it is possible that the expression variation that we
observed was due to gene dosage differences that are too complex for our computational
methods to properly detect but are, in effect, tagged by the associated CNVR.
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DISCUSSION
The central goal of our work was to estimate the functional impact of germ line copy
number variation in vivo. To achieve this goal, we first identified CNVRs in twenty inbred strains
at the highest resolution reported to date. We discovered 1,333 CNVRs spanning approximately
3% of the mouse genome. On average, there are over 300 CNVs per strain. As predicted, we
found that the frequency of CNVRs increased with decreasing CNVR length, but that short CNVs
account for only a small fraction of the total copy number variable sequence content of the
mouse genome. We speculate that this trend will hold as higher resolution technologies are
developed. Unexpectedly, we found that small CNVs (<10 kb) lack the enrichment of highly
homologous sequences that frequently flank, and are presumed to contribute to the formation of
medium (10-100 kb) and large (>100 kb) CNVs. Determining the mechanisms that generated
these CNVs would facilitate the design of targeted assays to detect new CNVs and provide a
better understanding of the forces that shaped the mouse genome. We are aware of only one
report documenting similar short deletions in a small number of human genomes and therefore a
mouse-to-human CNVR comparison will be informative as high-resolution human data become
available41. A caveat of our CNVR map is that, as is true for all comparative genomic
hybridization experiments, we were limited to finding variants in comparison to a reference
sequence; sequences that do not exist in the C57BL/6J genome but vary in copy number among
other strains were not detected. Therefore, the total extent of copy number variation relative to
the union of all inbred mouse genomes must await comprehensive sequencing of other strains.
However, a reasonable estimate of the amount of mouse genomic sequence lost in the
C57BL/6J strain is the amount of genomic material lost per strain relative to C57BL/6J, which
ranged from 16.8 to 33.8 Mb (mean = 25.5 Mb).
Using a relatively small number of inbred mouse strains, we found that all classes of
CNVs were associated with gene expression changes in a variety of tissues. We found that
28% of strain-specific expression traits were associated with copy number variation in the
hematopoietic progenitor/stem compartment, consistent with the 18% previously reported in
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human lymphoblastoid cell lines42. To validate these eQTLs, we inferred the CNVR genotypes
of the BXD RI panel and analyzed publicly available KLS expression data. Over 29% of the
testable KL eQTLs were supported in the BXD data set, a striking concordance given the
substantial experimental and biological differences between the studies. We also detected
many CNVR eQTLs in adipose tissue and hypothalamus, even though these data were
produced with different mice, using different expression platforms, and the eQTL analysis was
performed with 25% fewer strains. Much of the recent speculation on the potential impact of
CNVs on phenotypic variation has centered on gene-dosage effects43. However, we found that
only 7.3% of CNVR eQTLs contain the associated expression probe and therefore were due to
gene-dosage effects. Presumably, the remaining CNVR eQTLs reflect expression variation
mediated by alteration of regulatory material or local chromatin structure. This would be
consistent with a model where (subtle) alterations in expression patterns are better tolerated
than complete or partial gene gains or losses.
Some of the CNVR eQTLs reported here may be in linkage disequilibrium with another
allele causing the associated expression change, underscoring the need to characterize the
relationship between CNVs and other genetic variants. It is likely that there are additional
eQTLs not detected here: CNVRs that alter expression in only one or two strains, trans eQTLs,
eQTLs that associate with genes expressed in tissues not sampled here, and eQTLs with weak
effects. Increasing the number of strains and the tissues sampled would address some of these
limitations. However, extending this work to a much larger population with greater genetic
diversity (i.e., the Collaborative Cross44) would increase the power to detect trans and weaker
effects and therefore enable a clearer understanding the overall impact of CNVR on expression
variability. Future work must reach beyond identifying statistical associations to better
characterize the mechanisms by which a CNVR affects phenotypic (including expression)
variation. In addition to estimating the impact of CNVRs on expression variation, the CNVR
eQTLs reported here may be of practical value in identifying the causal variants in traditional
QTLs because they present plausible hypotheses linking genetic differences between inbred
strains to complex traits.
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METHODS
Mice
Male mice were obtained from The Jackson Laboratory (Bar Harbor, ME), housed in a
specific pathogen-free facility, and sacrificed at 8-10 weeks of age. The same individual mice
were used for both DNA- and RNA-based analyses. All experiments were performed in
compliance with the guidelines of the Animal Studies Committee at Washington University, St.
Louis, MO.

DNA preparation
DNA was prepared from spleen, liver, kidney, and tail by phenol-chloroform extraction,
and was quantified using UV spectroscopy (NanoDrop 1000,Thermo Scientific, Wilmington, DE).
Kidney DNA for aCGH experiments were pooled in equal masses from 2–6 individuals per
strain. Only individual samples passing NimbleGen quality control requirements were pooled.

aCGH analysis
A tiling-path CGH array for whole-genome analysis in mouse (mm8, NCBI Build 36) was
utilized (http://www.nimblegen.com). Isothermal probes from 45-75 bp were selected with a
median probe spacing of 1 kb. Labeling, hybridization, washing and array imaging were
performed as previously described45. Previously, we demonstrated that regions of the mouse
genome with high sequence divergence between the test and reference strains have lower aCGH
probe signal intensities and can, therefore, potentially disrupt the identification of CNVs16. Using
an imputed single nucleotide map46, we defined regions of high sequence divergence between
the test and reference genomes for input to wuHMM, a Hidden Markov Model algorithm for CNV
detection16. All putative wuHMM CNV calls with scores less than 1.5 or 1.9 (gains or losses,
respectively) were discarded, as we have previously shown that they contain a high number of
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false positive predictions. CNVRs were defined by merging overlapping wuHMM calls across all
individuals. To assess the complexity of the CNVRs, we calculated average boundary
concordances (the average of the length of the intersection of a CNV and CNVR divided by the
total CNVR length). CNVRs having average concordances <= 0.75 (Supplementary Figure 5)
comprised less than 23% of the CNVRs detected in this study. We refer to these regions as
‘complex’ and all other CNVRs as ‘simple’. All microarray data, aCGH and expression, is
available for download from GEO (http://www.ncbi.nlm.nih.gov/geo/) under series accession
GSE10656.

CNVR genotyping
Clustering of CNVRs was performed using partitioning among medoids (PAM) as
implemented in R17. The average silhouette function calculates the average between versus
within group distances and ranges from -1 to 1, with 1 representing perfect clustering17. We
modified this function to weight groupings by their agreement with wuHMM calls. We executed
PAM, varying the number of clusters from 2-7, and calculated the weighted average silhouette.
The number of clusters with the maximum, modified average silhouette was selected for the
number of genotypes per CNVR. Sometimes a clustering would result in a group of strains in
which no wuHMM call had been made, representing a new gain, loss or abnormal genotype.
These genotypes were disallowed and these strains were assigned into the same genotype label
as the reference strains. CNVRs with both average silhouettes < 0.3 and average scores < 2.0
were discarded, as they were likely to represent spurious clusters.

CNVR validation
61 simple CNVRs were randomly selected for validation from the set with average scores
between 1.3 and 3.3. These CNVRs ranged from 887 bases to 67 kb (2 to 47 aCGH probes) and
scored from 1.3 - 2.3 for gains, and 1.9 - 3.3 for losses. For qualitative PCR validation (losses
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only), primers were designed to target reference sequence within the predicted boundaries of the
CNVR, prioritizing amplicons near or overlapping the aCGH probes with the maximum log2-ratio
magnitudes. One to three amplicons were designed per CNVR. A positive control amplicon was
designed for a region with no predicted CNVs in any of the 20 strains (primer sequences in
Supplementary Table 8). For quantitative PCR (gains only), relative copy numbers were
determined by real-time PCR (qPCR) using TaqMan detection chemistry and the ABI Prism 7300
Sequence Detection System (Applied Biosystems, http://www.appliedbiosystems.org), as
previously described1. A CNVR loss was validated if no amplicon was produced using primers
targeted within predicted CNVR boundaries. A CNVR gain was validated when qPCR
demonstrated a >2-fold increase in inferred relative copy number relative to the reference strain.
We defined the false positive rate (FPR) as the number of false positives divided by the number
of gain and loss genotypes at or exceeding a given score threshold. The FPR for putative copy
number losses with scores between 2.0 and 2.5 was 25% (152/608 CNV calls tested). Nearly a
third of these amplicons (50/152) exhibited altered electrophoretic mobility consistent with the
CNV strain distributions predicted by aCGH analysis. To better understand this phenomenon, we
cloned and sequenced two of the amplicons from four affected strains and discovered three novel
SNPs in each amplicon which overlapped an aCGH probe sequence in the CNVR in each case.
Sequence divergence can disrupt probe hybridization resulting in decreased signal intensity and,
at times, false positive deletion calls. Further, we found a 14- and a 10-bp insertion near the
probe sequence in the affected strains, which accounted for the altered size of the amplicons.
The co-occurrence of SNPs and in/dels has previously been reported and their potential causal
relationship is under investigation47. For CNVRs with average scores exceeding 1.5 and 2.5 for
gains and losses, respectively, the FPR approached 0 (Supplementary Table 1). Therefore,
only calls that exceeded these thresholds were retained for further analysis.

Comparison to other studies
CNVR coordinates were translated from mm6 to mm8 using liftOver, when necessary
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(http://genome.ucsc.edu/cgi-bin/hgLiftOver). We defined sub-sets of CNVRs by selecting only
those CNVRs that have a gain, loss, or abnormal genotype in at least one of the strains in
common with another study. Overlap between studies was reported as either the total shared
sequence in the intersection of CNVRs or as the number of CNVRs that have overlapping
boundaries. For comparisons of CNV content by CNVR size, sequence overlap was determined
by calculating the total sequence intersection between only small, medium or large, highconfidence CNVRs and all CNVRs from other studies.
Sequence may be reported as copy number variable exclusively in other studies due to
differences in genome coverage20, de novo events22, or because lower resolution platforms tend
to over-estimate CNVR boundaries1,21. The comparison to a study that mainly targeted
segmental duplicated regions of the genome resulted in the lowest agreement (63.9%)20. Many
of these regions have sparse probe coverage on the platform that we utilized and therefore are
problematic regions in which to detect CNVs. The second lowest overlap (64.3%) was with a
study that specifically targeted the identification of de novo events in C57BL/6-derived strains22.
It is possible that the 36.7% of CNV content exclusive to that study was not detected here
because those sequences did not exist in, or comprised an undetectable fraction of the samples
used in our study. We also assessed the overlap between CNVRs in our study and others,
defined across all strains, to determine the overall consensus of reported copy number variation
in the inbred mouse genome. To perform this comparison, we first merged all CNVs from
previous studies into a single set of CNVRs finding that the amount of novel CNV sequence
content is relatively low (16%) (Supplementary Table 3).

Enrichment analysis
The association between CNVRs and genomic features was tested by randomly
permuting the chromosome and position of each CNVR 100 times and determining the
sequence content of the resulting region or flanking regions. Gene overlap enrichment was
tested similarly, except that the test statistic was the number of CNVRs per permutation that
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overlapped at least one gene using UCSC’s knownGene annotation
(http://genome.ucsc.edu/cgi-bin/hgGateway?org=Mouse&db=mm8).

Cell sorting and RNA extraction
Bone marrow cells were harvested from mouse femurs and stained with FITCconjugated lineage markers (Gr-1, CD19, B220, CD3, CD4, CD8, TER119, and IL-7Rα) and
APC-conjugated c-kit (BD Biosciences, San Diego, CA). Lineage-negative, c-kit positive cells
were enriched using a modified MoFlo high speed sorter (Cytomation, Fort Collins, CO). Total
RNA was prepared using Trizol LS (Invitrogen, Carlsbad, CA) and its concentration quantified
using UV spectroscopy (Nanodrop). Total RNA quality was then determined by Agilent 2100
Bioanalyzer (Agilent Technologies) according to the manufacturer’s recommendations.

Expression profiling
RNA transcripts were amplified by T7 linear amplification (MessageAmp TotalPrep
amplification kit; ABI-Ambion). First strand synthesis was primed with oligo-dT, followed by in
vitro transcription to generate amplified RNAs (aRNA). The aRNAs were then quantitated on a
spectrophotometer, and quality determined by Agilent 2100 bioanalyzer according to the
manufacturer’s recommendations. Hybridization to the MouseWG-6 v1.1 Expression Beadchip
(Illumina), washing, and signal detection were performed using standard protocols. Quantitated
data were imported into Beadstudio software (Illumina). On-slide spot replicates were averaged
by Beadstudio and individual spot data was reported. Probes were defined as ‘present’ in a
sample when the signal was significantly higher than in a set of negative control probes, (P <
0.05 after correcting for multiple tests). A probe was defined as present in a strain if it was
called ‘present’ in all replicate samples of that strain. The correlation of within-strain expression
profiles exceeded between-strain correlations in all but two strains (average within strain
correlation = 0.9782, average between-strain correlation = 0.9528), demonstrating that the
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expression profiles reflect biological variation and not technical artifacts (i.e., due to differences
in cell staining, sorting, RNA labeling, or hybridization).

eQTL Mapping
Expression quantitative trait mapping was implemented as previously described28,31,32
with the exception that CNVR instead of SNP genotypes were used as predictor variables. Null
distributions of F-statistics for CNVR-expression trait tests were generated by 10,000 random
permutations of expression values. The permutations were weighted according to strainrelatedness as defined using an imputed SNP map46 (exponent = 3 ) such that closely related
strains more frequently replaced each other than distantly related strains. All permutation
analyses were implemented on custom software and executed on a compute cloud
(http://aws.amazon.com/ec2). Often a single trait was tested against multiple CNVRs therefore
the permutation-derived P-values were corrected by applying the Holm multiple testing
correction separately for each trait.
BXD RI SNP genotype data was downloaded from:
http://www.genenetwork.org/dbdoc/BXDGeno.html. A CNVR genotype of ‘B’, ‘D’, or ‘U’ was
assigned for each CNVR to each strain if the two markers spanning the CNVR were both
C57BL/6J, both DBA/2J, or discordant, respectively. BXD KLS expression data was
downloaded from GEO, accession number GSE2031. Of the genes identified as having
significant associations with CNVRs in cis in the KL expression data set, only those that were
detected in at least 80% of the samples from either or both CNVR genotype groups were
assessed for concordant expression in the BXD KLS data. Association between KLS expression
and inferred CNVR genotype was performed as for KL expression data.

84

ACKNOWLEDGEMENTS
This work was supported in part by a grant from the NIH/NCI (CA101937). P.C was supported
in part by the National Human Genome Research Institute (T32 HG000045) and a Kauffman
Fellowship. Mice were kindly provided through a collaboration with the Mouse Phenome Project
(The Jackson Laboratory, Bar Harbor, ME). Additional mice were provided by Ming You. We
thank Tim Ley, Dan Link, and Matt Walter for helpful discussions. Cell sorting was performed by
the High Speed Cell Sorter Core in the Alvin J. Siteman Cancer Center at Washington University
School of Medicine. The Siteman Cancer Center is supported in part by an NCI Cancer Center
Support Grant (P30 CA91842).

85

REFERENCES
1.

Graubert, T.A. et al. A High-Resolution Map of Segmental DNA Copy Number Variation
in the Mouse Genome. PLoS Genetics 3, e3 (2007).

2.

Li, J. et al. Genomic segmental polymorphisms in inbred mouse strains. Nat Genet 36,
952-954 (2004).

3.

Perry, G.H. et al. Hotspots for copy number variation in chimpanzees and humans. Proc
Natl Acad Sci U S A 103, 8006-11 (2006).

4.

Redon, R. et al. Global variation in copy number in the human genome. Nature 444,
444-54 (2006).

5.

Snijders, A. et al. Mapping segmental and sequence variations among laboratory mice
using BAC array CGH. Genome Res 15, 302-311 (2005).

6.

Dopman, E.B. & Hartl, D.L. A portrait of copy-number polymorphism in Drosophila
melanogaster. Proc Natl Acad Sci U S A 104, 19920-5 (2007).

7.

Emerson, J.J., Cardoso-Moreira, M., Borevitz, J.O. & Long, M. Natural selection shapes
genome-wide patterns of copy-number polymorphism in Drosophila melanogaster.
Science 320, 1629-31 (2008).

8.

Guryev, V. et al. Distribution and functional impact of DNA copy number variation in the
rat. Nat Genet 40, 538-45 (2008).

9.

Iafrate, A.J. et al. Detection of large-scale variation in the human genome. Nat Genet 36,
949-51 (2004).

10.

Sebat, J. et al. Large-scale copy number polymorphism in the human genome. Science
305, 525-8 (2004).

11.

Aitman, T.J. et al. Copy number polymorphism in Fcgr3 predisposes to
glomerulonephritis in rats and humans. Nature 439, 851-5 (2006).

12.

McCarroll, S.A. et al. Deletion polymorphism upstream of IRGM associated with altered
IRGM expression and Crohn's disease. Nat Genet (2008).

13.

Singleton, A.B. et al. alpha-Synuclein locus triplication causes Parkinson's disease.
Science 302, 841 (2003).

14.

Walsh, T. et al. Rare structural variants disrupt multiple genes in neurodevelopmental
pathways in schizophrenia. Science 320, 539-43 (2008).

15.

Bogue, M.A. & Grubb, S.C. The Mouse Phenome Project. Genetica 122, 71-4 (2004).

16.

Cahan, P. et al. wuHMM: a robust algorithm to detect DNA copy number variation using
long oligonucleotide microarray data. Nucleic Acids Res 36, e41 (2008).

17.

Kaufman, L. & Rousseeuw, P.J. Finding Groups in Data: An Introduction to Cluster
Analysis, (Wiley, New York, 1990).

18.

Conrad, D.F., Andrews, T.D., Carter, N.P., Hurles, M.E. & Pritchard, J.K. A highresolution survey of deletion polymorphism in the human genome. Nat Genet 38, 75-81
(2006).

19.

Korbel, J.O. et al. Paired-end mapping reveals extensive structural variation in the
human genome. Science 318, 420-6 (2007).

20.

She, X., Cheng, Z., Zollner, S., Church, D.M. & Eichler, E.E. Mouse segmental
duplication and copy number variation. Nat Genet 40, 909-14 (2008).

21.

Cutler, G., Marshall, L.A., Chin, N., Baribault, H. & Kassner, P.D. Significant gene
content variation characterizes the genomes of inbred mouse strains. Genome Res 17,
1743-54 (2007).

22.

Egan, C.M., Sridhar, S., Wigler, M. & Hall, I.M. Recurrent DNA copy number variation in
86

the laboratory mouse. Nat Genet 39, 1384-9 (2007).
23.

Watkins-Chow, D.E. & Pavan, W.J. Genomic copy number and expression variation
within the C57BL/6J inbred mouse strain. Genome Res 18, 60-6 (2008).

24.

Lupski, J.R. Genomic disorders: structural features of the genome can lead to DNA
rearrangements and human disease traits. Trends Genet 14, 417-22 (1998).

25.

Sharp, A.J. et al. Segmental duplications and copy-number variation in the human
genome. Am J Hum Genet 77, 78-88 (2005).

26.

Akagi, K., Li, J., Stephens, R.M., Volfovsky, N. & Symer, D.E. Extensive variation
between inbred mouse strains due to endogenous L1 retrotransposition. Genome Res
18, 869-80 (2008).

27.

Chambers, S.M. et al. Hematopoietic Fingerprints: An Expression Database of Stem
Cells and Their Progeny. Cell Stem Cell 1, 578-591 (2007).

28.

McClurg, P. et al. Genomewide Association Analysis in Diverse Inbred Mice: Power and
Population Structure. Genetics 176, 675-683 (2007).

29.

Wu, C. et al. Gene set enrichment in eQTL data identifies novel annotations and
pathway regulators. PLoS Genet 4, e1000070 (2008).

30.

Kleinjan, D.A. & van Heyningen, V. Long-range control of gene expression: emerging
mechanisms and disruption in disease. Am J Hum Genet 76, 8-32 (2005).

31.

Pletcher, M.T. et al. Use of a dense single nucleotide polymorphism map for in silico
mapping in the mouse. PLoS Biol 2, e393 (2004).

32.

McClurg, P., Pletcher, M.T., Wiltshire, T. & Su, A.I. Comparative analysis of haplotype
association mapping algorithms. BMC Bioinformatics 7, 61 (2006).

33.

Holm, S. A simple sequentially rejective multiple test procedure. Scandinavian Journal of
Statistics 6, 65-70 (1979).

34.

Bystrykh, L. et al. Uncovering regulatory pathways that affect hematopoietic stem cell
function using 'genetical genomics'. Nat Genet 37, 225-32 (2005).

35.

Bishop, T.R., Cohen, P.J., Boyer, S.H., Noyes, A.N. & Frelin, L.P. Isolation of a rat liver
delta-aminolevulinate dehydrase (ALAD) cDNA clone: evidence for unequal ALAD gene
dosage among inbred mouse strains. Proc Natl Acad Sci U S A 83, 5568-72 (1986).

36.

Bishop, T.R., Miller, M.W., Wang, A. & Dierks, P.M. Multiple copies of the ALA-D gene
are located at the Lv locus in Mus domesticus mice. Genomics 48, 221-31 (1998).

37.

Schadt, E.E. et al. Genetics of gene expression surveyed in maize, mouse and man.
Nature 422, 297-302 (2003).

38.

Hovatta, I. et al. Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice.
Nature 438, 662-6 (2005).

39.

Ohtsuka, M., Inoko, H., Kulski, J.K. & Yoshimura, S. Major histocompatibility complex
(Mhc) class Ib gene duplications, organization and expression patterns in mouse strain
C57BL/6. BMC Genomics 9, 178 (2008).

40.

Kumar, P.P. et al. Functional interaction between PML and SATB1 regulates chromatinloop architecture and transcription of the MHC class I locus. Nat Cell Biol 9, 45-56
(2007).

41.

Hinds, D.A., Kloek, A.P., Jen, M., Chen, X. & Frazer, K.A. Common deletions and SNPs
are in linkage disequilibrium in the human genome. Nat Genet 38, 82-5 (2006).

42.

Stranger, B.E. et al. Relative impact of nucleotide and copy number variation on gene
expression phenotypes. Science 315, 848-53 (2007).

43.

Korbel, J.O. et al. The current excitement about copy-number variation: how it relates to
gene duplications and protein families. Curr Opin Struct Biol 18, 366-74 (2008).

44.

Churchill, G.A. et al. The Collaborative Cross, a community resource for the genetic
87

analysis of complex traits. Nat Genet 36, 1133-1137 (2004).
45.

Selzer, R.R. et al. Analysis of chromosome breakpoints in neuroblastoma at subkilobase resolution using fine-tiling oligonucleotide array CGH. Genes Chromosomes
Cancer 44, 305-19 (2005).

46.

Szatkiewicz, J.P. et al. An imputed genotype resource for the laboratory mouse. Mamm
Genome 19, 199-208 (2008).

47.

Tian, D. et al. Single-nucleotide mutation rate increases close to insertions/deletions in
eukaryotes. Nature 455, 105-8 (2008).

88

Table 1: CNVR eQTL characteristics.
Expression Probes

CNVRs

Tissue

Probes

Present

Strainspecific

Hematopoietic

46,629

13,588

1,469

958

408 (391)

484

214

Adipose

32,533

10,040

4,083

2,056

181 (177)

466

116

Hypothalamus

32,533

14,871

2,879

789

78 (76)

440

66

In cis

eQTL

Testable
CNVRs

eQTL
CNVRs

“In cis” is the number of expression probes within 2 Mb of a CNVR.
Only CNVRs that have greater than two strains per genotype group are considered for eQTL mapping
(“Testable CNVRs”).
eQTL is the number of expression probes (genes) that are significantly associated with a CNVR (P < 0.05).
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Table 2: Subset of CNVR-eQTLs in hematopoietic stem/progenitor cells,
hypothalamus, and adipose tissues.
Gene symbol

CNVR
ID

Chr

Hypothalamus
Proximity
2
R
(Kb)

Hematopoietic
Proximity
2
R
(Kb)

Position
(Mb)

R

2

Adipose
Proximity
(Kb)

Alad

754

4

Glo1

3001

17

30 0.81

0

0.87

0 0.86

0

Sox13

216

1

135 0.42

5

0.30

5

0

2310009E04Rik

766

4

97 0.35

1,149

0.48

1149

0

Thumpd1

1383

7

119 0.28

423

0.26

422

0

62 0.76

0

0.66

0 0.41

0

Ifi205

127

1

177 0.39

1,181

0.42

Cstf3
Hdc

420

2

104 0.24

61

0.29

1,308
5

432

2

128 0.26

1,761

0.26

1,761

Gbp1

640

3

143 0.96

0

0.91

0

Hdhd3

754

4

62 0.49

0

0.43

0

Trim56

925

5

137 0.78

37

0.37

37

Gtf3a
Capg

931

5

146 0.50

764

0.28

763

1077

6

72 0.94

473

0.69

468

Mir16

1383

7

119 0.43

592

0.58

598

Hemk1

1749

9

107 0.94

233

0.30

233

Pbx1

232

1

171

0.47

794 0.31

794

Trim34

1372

7

104

0.54

263 0.76

263

4833420G17Rik

2405

13

121

0.75

1 0.38

1

Paip1
Zfr

2405

13

121

0.35

36 0.51

36

2719

15

12

0.49

474 0.36

474

Cxadr

2872

16

79

0.68

477 0.47

477

Sytl3

2978

17

6

0.47

0 0.37

0

H2-T23

3014

17

36

0.47

114 0.55

114

All eQTLs listed in the table are significant at an alpha < 0.05 after correcting for multiple tests. R2 is the
correlation coefficient for the CNVR-to-eQTL association. Proximity is the number of bases between the nearest
boundaries of the expression probe and CNVR. Gene dosage eQTLs have a proximity = 0 (Alad, Glo1, Gbp1,
Hdhd3, and Sytl3).
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Figure 1. CNVR genotyping. Log2-ratio plots of the test versus reference (C57BL/6J) aCGH
signal intensities. All twenty strains are shown in each plot. Horizontal lines represent wuHMM
segmentation calls, which are made independently for each strain. CNVs are merged into CNVregions (CNVRs), represented as vertical dotted lines. CNVR genotypes (see Methods) are
indicated by probe coloring and strains are indicated by probe shading. (a) A 30 kb simple
CNVR gain present in 16 strains. wuHMM call boundaries largely agree with the CNVR
boundaries, resulting in a high average concordance (91.6%). (b) A 12 kb simple CNVR loss
occurring in 8 strains. (c) A 39 kb simple gain/loss CNVR called as a ‘gain’ in 7 strains and as a
‘loss’ in 3 strains. (d) A 416 kb complex CNVR assigned 5 different genotype groups.
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Figure 2. Location of CNVRs in the inbred mouse genome. The ideograms depict
chromosomal locations of CNVRs in the autosomes and X chromosome from 20 inbred strains.
Gains relative to the reference genome (C57BL/6J) are green lines, losses are red, and complex
CNVRs are blue. The height of the lines reflects the number of strains in which the genotype call
is made.
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Figure 3. Distribution of CNVR sizes. (a) Length distribution of CNVRs (on log10 scale). Most
CNVRs are shorter than 10 kb. (b) Length distribution of CNVRs separated by CNVR genotype.
CNVRs are divided into small (<10 kb), medium (10 kb ≥ CNVR length < 100 kb), or large (≥100
kb). Frequency is indicated by solid bars (left axis) and sequence content by hatched bars (right
axis). Most CNVRs are small losses, but most of the copy number variable sequence in the
mouse genome is in large, complex CNVRs. (c) The number of gain, loss, or abnormal CNVR
genotypes and the copy number variable sequence per strain. C57/J and C58/J, the most
closely related strains to C57BL/6J, have fewer CNVs than more distantly related strains.
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Figure 4. Co-localization of CNVRs with other genomic elements. The enrichment or
depletion of segmental duplications (SD), LINEs, SINEs, LTRs, and genes as annotated in
UCSC’s knownGene track (KG) in CNVRs was tested by permuting the location of CNVRs. The
percent of the CNVR sequence comprised of SD, LINE, SINE, and LTR was compared to the
permuted background, as was the number of CNVRs that overlapped at least one gene. The
ratio of permuted to observed results (log10 scale) are shown, where a negative value indicates
depletion and positive indicates enrichment. * P < 0.05. ** P < 0.01.
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Figure 5. Tissue-specific CNVR eQTLs. Overlap of eQTL genes in hematopoietic
stem/progenitors, adipose, and hypothalamus. Most eQTL genes are tissue- specific, implying
that other factors can influence these expression traits.
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Figure 6. CNVR eQTLs. (a) Top: Log2-ratio plot of a 481 kb CNVR containing the complete
coding sequence of Glo1 (location is indicated by horizontal line). Positions of Illumina (blue
asterisk) and Affymetrix (green asterisk) expression probes are shown. Bottom: Glo1
expression in hematopoietic stem/progenitors, adipose tissue, and hypothalamus. Expression is
significantly correlated with the CNVR gain. (b) Top: Log2-ratio plot of a 24 kb CNVR
containing the 3’ exon and UTR of Gbp1. A gain is called in 8 strains. Bottom: Gbp1 expression
in the same tissues; expression is significantly correlated with the CNVR gain in hematopoietic
stem /progenitors and adipose tissue. Dotted line represents the mean detection threshold
across all arrays.
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Supplementary Figure 1. Log2 plots for all CNVRs. Log2-ratio plots of the test versus
reference (C57BL/6J) aCGH signal intensities for all 1,329 high-confidence CNVRs. All twenty
strains are shown in each plot. Horizontal lines represent wuHMM segmentation calls, which
are made independently for each strain. CNVs are merged into CNV-regions (CNVRs),
represented as vertical dotted lines. CNVR genotypes (see Methods) are indicated by probe
coloring and strains are indicated by probe shading. Available online at:
http://graubertlab.dom.wustl.edu/PDF_Docs/Supplementary%20Figure.pdf
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Supplementary Figure 2. Distribution of copy number variable sequence content by
CNVR size across strains. CNVs are separated by size. Most CNVs are small or medium in
all strains.
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Supplementary Figure 3. Validation of cell sort purity by gene expression profile. The
log2 gene expression values of the cell surface markers utilized in the hematopoietic
progenitor/stem cell sort strategy from all 48 samples. c-Kit, a primitive hematopoietic marker, is
highly expressed in the samples. The lineage makers genes (Gr-1, CD19, B220, CD3, CD4,
CD8, and IL-7Rα) are either expressed at low levels (Gr-1) or below or near the level of
detection (all CD19, B220, CD3, CD4, CD8, and IL-7Rα). No probe for Ly76 (Ter119) was on
the Illumina expression array.
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Supplementary Figure 4. Relationship between CNVR and eQTL by distance and effect
size. Top left: Frequency of hematopoietic eQTLs as a function of distance between the
expression probe and CNVR. Most eQTLs do not overlap the associated expression probe. Top
right: Hematopoietic eQTL effect size (correlation coefficient) as a function of distance between
the expression probe and CNVR. The effect size significantly decreases with increasing
distance. Middle row: Same as above for adipose tissue. Bottom row: same as above for
hypothalamus.
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Supplementary Figure 5. Concordance between CNVRs and individual CNV boundaries.
Average concordance is the average of wuHMM call lengths divided by the CNVR length and is
used to distinguish between ‘complex’ (average concordance ≤ 0.75) and ‘simple’ (average
concordance > 0.75) CNVRs. Left: average concordance histogram prior to filtering calls based
on empirically derived score thresholds. Right: average concordance histogram after applying
the score thresholds (>1.5 for gains, >2.5 for losses).
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INTRODUCTION

Therapy-related acute myeloid leukemia (t-AML) is a secondary malignancy attributable to the
chemotherapeutic treatment of an initial disease. Therapy-AML comprise 5-20% of all AML
cases and its prevalence is increasing along with the population undergoing chemotherapy1,2.
While there is evidence that chemotherapy regimen3 and genetic background4 contribute to tAML, little else is known definitively regarding susceptibility. Gaining a better understanding of tAML susceptibility factors is a pressing concern as it may lead to prevention strategies and
provide insight into the genesis of de novo AML.
One class of chemotherapeutic associated with t-AML is the alkylators (i.e. melphalan,
busulfan, thiotepa). The therapeutic effect of alkylator agents is believed to result from the
formation of DNA adducts and single and double-strand breaks, which trigger apoptosis or growth
arrest5. Based on this presumed mechanism of alkylator action, genes involved in DNA repair6,
response to oxidative stress7, and drug metabolism8 have been investigated as mediators of
susceptibility in candidate gene studies, with largely inconclusive results. A recent study in our
lab investigated the genetic basis of t-AML susceptibility using inbred mice9. In this study, eight
to twelve individual mice from each of 20 inbred strains were treated with the alkylating agent Nnitroso-N-ethylurea (ENU), a potent mutagen with a propensity to cause AT:TA transversions and
AT:GC transitions10. Mice were monitored for the development of MDS and AML for up to 16
months post ENU exposure. Myeloid tumors varied by strain, supporting the hypothesis of a
strong genetic component in t-AML susceptibility. Although much has been learned from the
combined efforts of candidate gene and genome-wide studies to elucidate the basis of t-AML
susceptibility, major contributing factors to t-AML susceptibility have yet to be identified.
We hypothesized that the pre-exposure transcriptional state of hematopoietic stem and
progenitor cells, the putative target of leukemogenesis11, underlies variation in susceptibility to tAML. A pre-exposure transcriptional basis of susceptibility would be expected if a rapid response
is critical in determining a cell’s ultimate fate upon mutagen exposure. This hypothesis is
consistent with the observations that genes critical to surviving genotoxic stress in yeast are not
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differentially expressed upon exposure12. A similar situation has been reported in human
lymphoblastoid, in which the pre-exposure transcriptional state of the cell more accurately
predicts survival than the post-exposure state13.
In this study, we apply an integrative genomics approach14 to identify and prioritize
genetic and transcriptional networks underlying t-AML susceptibility in mice. By linking expression
profiles and complex traits to common genomic loci, this method can ameliorate some of the
limitations inherent in genetic association and expression profiling studies15-19. When combined
with network analysis, this methodology has proven useful in elucidating the molecular networks
underlying several complex traits20,21.
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RESULTS

Expression quantitative trait loci in hematopoietic stem and progenitor cells
Previously, we reported the association 408 expression traits (391 genes) with 214 DNA copy
number variant regions (CNVRs) in kit+/lineage- (KL) cells22. However, this cis-eQTL map does
not include genetic variation that is not captured by the CNVRs reported therein (i.e. SNPs). To
derive a more complete map of cis-eQTLs in this population, we used publicly available SNP data
from 48 classical inbred strains to map SNP-based eQTLs23. The SNP resource includes
132,285 SNPs per genome, of which 115,009 we considered informative (as defined in Methods).
Prior to eQTL mapping, we used a simple merging algorithm to iteratively join adjacent SNPs into
haplotype blocks. This algorithm results in haplotype blocks in which the genotypes of a
complete set of SNPs is predictable to a given level of accuracy. We selected a threshold such
that for a given block, we can accurately predict the genotype of every SNP in all 48 strains with
at most one error (Figure 1A). The 23,884 resulting haplotype blocks are comprised of 1 to 62
SNPs (mean=4.82, median=4) (Figure 1B). There are 2 to 6 haplotypes per block (mean=3.92,
median=4) (Figure 1C). 9,324 blocks have one error, and the remaining 14,560 have zero. Of
the 7,405 haplotype blocks within 250 Kb of a CNVR boundary, only 39 have genotypes that
perfectly correlate with CNVR genotypes (Figure 1D). We speculated that the low correlation is
due to the fact that using all 48 classical inbred strains in the haplotype block construction
resulted in higher numbers of haplotype labels. Therefore, we also derived a haplotype block
map using only the 20 strains from the CNVR study. However, this analysis resulted in highly
similar results in terms of the map and haplotype correlation with CNVR genotypes (data not
shown). This suggests in current data sources, CNVRs and SNPs represent distinct sources of
genetic variation in the mouse genome. We used the 48-strain haplotype resource to map KL
expression traits to SNP-based haplotypes, as previously described22. We considered only ciseQTL-associated genes, as it has been shown that trans-eQTLs contain a large proportion of
false positives24. We found 127 associations between expression traits and haplotypes, after
selecting the most significant association per trait.
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Global pre-exposure transcriptional state of hematopoietic stem and progenitor cells is
associated with t-AML susceptibility
We performed gene expression profiling on 20 inbred strains listed as Priority 1-4 from the Mouse
Phenome Database 25. Two-to-three biological replicates arrays were analyzed per strain. This
GEP data was previously published22. We excluded wild-derived strains from this analysis
because the extent of genetic differences makes difficult the interpretation of aCGH, GEP, and
eQTL mapping analysis. Fifteen of the strains were previously assayed for susceptibility to t-AML
after exposure to ENU9. Unsupervised clustering of gene expression profiles largely separated
susceptible from resistant strains (Figure 2A). The probability that the unsupervised clustering of
expression profiles would reflect susceptibility status to the extent observed is < 0.01 (10,000
permutations, see Methods and Supplementary Figure 1A). Further, this clustering is not
observed in other tissues that are highly unlikely to be involved in leukemogenesis, the
hypothalamus and adipose tissue, nor does it reflect SNP-based strain distances (Supplementary
Figure 1B-D). Taken together, this supports the notion that the KL clustering of susceptible
strains is not due to sequence polymorphisms effecting target hybridization26 but rather reflects
tissue-specific differences in transcript abundance between inbred strains27. Additionally, this
observation suggests that the pre-exposure expression differences of many genes, rather than
only a few, segregate the KL cells of susceptible versus resistant strains.
Next, we sought those genes that are differentially expressed between susceptible and
resistant strains in KL cells. We identified 917 differentially expressed genes (976 probes) at an
FDR threshold of 5% (Supplementary Figure 2 and Supplementary Table 1). The differentially
expressed genes are enriched in several GO-annotated biological processes (Table 1), including
the GO terms ‘apoptotic program’ and ‘nucleotide metabolic process’. The Kegg pathways
‘Pyrimidine metabolism’ and Colorectal cancer’ were also enriched. ‘Acute myeloid leukemia’,
‘Apoptosis’, and ‘p53 signaling’ are biologically plausible pathways that were enriched at least
two-fold in the differentially expressed genes, however none of these pathways passed the FDR
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< 25% threshold. GO-apoptosis-annotated genes included both cell-intrinsic and extrinsic factors
(Figure 2B).

Integrated cis-eQTL mapping identifies candidate drivers of susceptibility
There are 45 candidate driver genes (45 probes) that are both differentially expressed and linked
to at least one eQTL. We refer to these genes as anchors throughout the text. 37 are linked to
CNVR-eQTLs; the remaining 8 are linked to haplotype-eQTLs. To validate the cis-eQTL
associations, we mined publicly available expression data representing hematopoietic stem,
progenitor, erythroid and myeloid populations from the BXD recombinant inbred panel28.
Because this data was generated using the same GEP platform as our KL data, we were able to
ask how our kit/lineage population is related to these more purified populations (Supplementary
Figure 3). As expected, our KL expression profiles cluster most closely with progenitor profiles
and are distinct from both erythroid and myeloid lineages. For each candidate driver, we tested
the association between BXD genotypes of SNPs within 2 Mb and driver expression. We found
that 30 of the 45 drivers were significantly associated with at least one SNP within 2 Mb in at least
one of the hematopoietic compartments (26 in either Stem or Progenitor), supporting the
hypothesis that expression differences of the anchor are caused by locally encoded genetic
29,30

variation. Out of the total of 480 testable eQTLs-transcript associations, 300 (62.5%) were

replicated in at least one of the hematopoietic data sets.

Anchored network analysis identifies t-AML susceptibility expression modules
Next, we hypothesized that expression differences of anchors would have multiple, downstream
transcriptional effects. For each anchor, we identified correlated expression profiles (FDR < 1%) ,
resulting in 30 sets of co-expressed genes or modules. The number of targets per module
ranged from 3 to 607 (mean=113, median=72). We reasoned that true response genes will
exhibit association with driver expression even when the remaining genome is randomly shuffled,
as is true in the BXD recombinant inbred cross. For each module, we tested the association
between expression of the anchor and each response transcript in each of the BXD
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hematopoietic populations. We removed target genes from modules that were not associated
with driver expression in at least one compartment (FDR < 25%) (Table 2). We also used a
previously described co-expression network algorithm to derive modules of correlated genes29,30
independent of linkage to eQTLs. We filtered these modules on the basis of their reproducibility
in the GdH datasets and compared the resulting modules with the anchored expression networks.
The WGCNA modules are highly similar to the anchored modules in gene content, suggesting
that the discovered co-expression structure is robust to different algorithms (data not shown).
The expression of each anchor gene is, by definition, associated with susceptibility
status. However, the strength of the association between the target genes of an anchored
module and susceptibility is unknown. To determine these values, we first computed eigengenes
from each module30. Then, we ranked anchored modules according to differential expression of
the module’s eigengene and susceptibility status. Using both KEGG and GO annotations, we
found that 8 anchored modules were enriched in at least one annotation. We visualized the
anchored susceptibility modules as networks (Figure 3A), displaying the correlation between
anchored modules and the strength of association between anchored modules and susceptibility
status. We also visualized a subset of the anchored susceptibility network, focusing on
biologically compelling modules (Figure 3B and 3D).
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DISCUSSION

There is accumulating evidence that many genetic contributors to complex traits are not proteincoding changes31. If true, then the only other class of genetic events that can effect phenotype
must, at some level, impact expression (i.e. eQTLs). Hypothesizing that such events contribute
to t-AML susceptibility, we took an integrative genomics approach to identify and prioritize
candidate genetic and transcriptional networks. The first step in this approach was to identify
eQTLs in hematopoietic stem and progenitor cells, the likely target of leukemic transformation.
Previously, we described a CNVR-eQTL map in classical inbred mice. In the current work, we
expanded this map to include SNP-based haplotype-eQTLs. In deriving the mouse haplotype
map, we found surprisingly little correlation between haplotypes and neighboring CNVRs. This is
in contrast to human studies, where nearly 75% of common CNVRs are estimated to be in
linkage disequilibrium with neighboring SNPs32. This suggests that at the currently available
resolution and coverage (and genotyping accuracy), mouse haplotypes and CNVRs represent
distinct sources of genetic information. We found two-fold more CNVR-eQTLs than haplotypebased eQTLs (401 vs. 167). It is tempting to speculate that this difference in eQTL types is
because CNVRs have a stronger impact on expression in cis and therefore are more likely to be
detected as eQTLs. However, the difference could largely be due to the reduced power to detect
haplotype-eQTLs because of the exacerbated multiple testing problem that comes with
performing approximately 20 times more statistical tests. Greater than 60% of the eQTLs were
reproducible in an independent dataset. This is a conservative estimate of the true validation rate
because only genetic differences between C57BL/6J and DBA/2J are present in the validation
data.
The second step in the integrative approach was to find genes differentially expressed
between susceptible and resistant strains. Because unsupervised clustering of all expressed
transcripts grouped strains largely by susceptibility status, we expected to find a large number of
genes associated with susceptibility status. Greater than 7% of the expressed transcripts are
differentially expressed (976/13,496). These genes are enriched in several, independent
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biological processes, most notably apoptosis. Among the intrinsic apoptosis genes are Caspase
9 (Casp9), B-cell leukemia/lymphoma 2 (Bcl-2), BCL2-associated agonist of cell death (Bad),
BCL2-associated X protein (Bax), and mutS homolog 6 (Msh6). Msh6 is a member of the mutSα
DNA mismatch recognition complex that has been shown mediate apoptosis in certain
contexts33,34. Notably, the absence of mutSα activity in myeloid progenitors results in the
complete loss of O6-methylguanine (O6MeG)-mediated cytotoxicity35. That resistant strains have
higher expression of Msh6 suggests that upon alkylator exposure, resistant strains may recognize
DNA damage and respond appropriately (i.e. die) whereas the KL cells of susceptible strains may
tend to live, accumulate mutations, and transform. In KL cells, almost all susceptible strains have
no detectable expression of Casp9, a critical initiator of programmed cell death, suggesting that
these cells (low-to-no Casp9 expression) are less primed for Casp9-dependent apoptosis.
However, susceptible strains had decreased expression of Bcl-2, an anti-apoptotic gene, and
increased expression of Bad and Bax, both pro-apoptotic genes. This would suggest that the KL
compartment of susceptible strains is more ‘primed’ for cell death, consistent with the observation
that the SWR/J allele of Bcl2 confers increased survival in an F2 cross model of t-AML36.
However, this pattern of expression is contrary to the prediction based on Casp9 expression,
possibly indicating a regulatory feedback loop to compensate for the apparent absence of Casp9
in susceptible strains. Taken together, these results illustrate the complexity in assessing the
relative functional activity of a cell population (i.e. readiness to commit to apoptosis) given a
snapshot of the population’s static transcriptional state. Experiments to test variation in alkylatorinduced apoptosis will help to resolve this apparent paradox.
Differential expression and gene enrichment analysis highlighted several biologically
plausible pathways that may underlie t-AML susceptibility. However, it remained unclear which
pathway members, if any, are causal contributors to the phenotype, as illustrated by the complex
expression patterns of the intrinsic apoptosis genes. More broadly, the role and relative
importance of each of the 917 differentially expressed genes in susceptibility remained
undetermined. We hypothesized that important transcriptional regulators of susceptibility affect
the expression of multiple downstream genes. Therefore, as the third step in the integrated
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genomics approach, we identified networks of genes that are significantly correlated with
candidate susceptibility drivers. Drivers are those genes that are both differentially expressed
and associated with eQTLs. We trimmed the networks of response genes whose expression was
not reproduced in independent data sets.
One of the benefits of the integrative genomics approach is that it can implicate biological
processes that would not have been detected using differential expression alone. Susceptibility
networks are enriched genes involved in DNA repair, base excision repair, apoptosis, and cell
cycle, among other annotations. A second benefit of the integrated approach is that it
differentiates between upstream (drivers) and response genes. This is proving useful in
prioritizing apoptosis-related genes for experimental validation. Although Casp9 and Bcl2 are
differentially expressed, Casp9 is also the candidate driver of module A_33, the module most
strongly associated with susceptibility status. We speculate that perturbation of candidate
drivers, such as Casp9, are more likely to be informative in elucidating susceptibility than
response genes (i.e. Bcl2).
Network analysis allowed us to predict the function of uncharacterized genes. For
example, A630001G21Rik is expressed primarily in primitive hematopoietic and B-cells (ref GNF),
yet its function is undetermined. Our analysis places it as the driver of module A_12, which is
enriched in apoptosis-related genes including Bcl2. Therefore, A630001G21Rik may play
previously unknown role in regulation of Bcl2 expression and apoptosis activity. Similarly,
Cytoskeleton-associated protein-like 2 (Ckap2l) is the driver of the largest module, A_16,
enriched in both cell cycle and DNA repair genes (Figure 3B). Although Ckap2l is highly
expressed in hematopoietic progenitors37, its functions are unknown (GNF). Its closest ortholog,
Ckap2, is highly expressed in mouse stem cell lines and has detectable expression in
hematopoietic progenitors, bone marrow, osteoclasts, osteoblasts, and macrophages37. There is
a growing body of literature suggesting that Ckap2 (also known as Tumor-associated
microtubule-associated protein) is involved in cell cycle progression38-40. It has long been
recognized that disruptions to normal cell cycle parameters can impact cancer susceptibility41. It
is possible that Ckap2l contributes to cell cycle regulation in HSCs and progenitors, and that
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genetic disturbances to its expression alter t-AML susceptibility. Experiments that perturb
expression of driver genes such as Casp9 and Ckap2l to assess their impact on module
expression and activity are the next logical steps in determining the role of candidate networks in
susceptibility. If such experiments demonstrate a causal link between driver genes and module
expression, then moving forward to more definitive transplantation experiments will be warranted.
A drawback to the anchored network approach, as currently implemented, is that it
assumes there is only a single anchor per module. In cases where CNVRs disrupt local
chromosome structure, its is possible that a single genetic event impacts the expression of
multiple neighboring genes (Figure 3C). In module A_37, we found that 10 response genes are
located with 7 Mb of this CNVR (Figure 3D). This module warrants special attention because it
includes poly (ADP-ribose) polymerase family member 2 (Parp2, the anchor) and
apurinic/apyrimidinic endonuclease 1 (Apex1), both members of the base excision repair
pathway42,43. Both genes have lower expression in susceptible strains, again suggesting that
lowered overall DNA damage response promotes susceptibility.
A caveat to the current work is that maps of genetic variation in the mouse genome are
incomplete. It is possible that un-captured genetic variants may be the ultimate cause of the
observed co-expression networks. And they may mediate their impact through mechanisms
other than altering the expression of drivers. In the extreme case, all modules may not be
controlled by driver expression, but by undetected causes. Nevertheless, the modules
themselves are still informative in that they describe sets of coordinately regulated genes that,
collectively, are associated with both susceptibility and biologically plausible processes and
pathways.
To our knowledge, this is the first report of an integrative genomics approach to dissect
the role of the pre-exposure transcriptional state in t-AML susceptibility. From a clinical
perspective, t-AML are important because they are generally incurable and median survival time
from diagnosis is eight months3. But because t-AML are clinically induced malignancies, they are
by definition preventable. Therefore, a long-term goal of t-AML research is to gain sufficient
understanding of susceptibility factors in order to make worthwhile the personalization of
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chemotherapeutic regiments based on t-AML risk. The transcriptional networks and their
candidate drivers described here are an important early step towards gaining such an
understanding.
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METHODS

Genomic coordinates of 1,333 CNVRs were mapped from mm8 to mm9 using liftOver. 31
CNVRs were unmapped and dropped from further analysis. To derive haplotype blocks, SNPs
for the haplotype map construction were downloaded from Broad Institute23. Only SNPs from 48
non-wild-derived strains were used. SNPs that were contained within CNVRs, had minor allele
frequencies < 5%, or were not genotyped in 25% or more of strains were considered to be
uninformative and were excluded from further analysis. The following steps were performed to
simultaneously group SNPs into blocks and to assign haplotype to strains:

(1) Begin with the first informative SNP on a chromosome.
(2) If the number of SNPs in the current block is 1 then go to (3). Otherwise, go to (4).
(3) Group strains by genotype and add the next consecutive SNP to the current block.
(4) Cluster strains by SNP-based distance using PAM (number of clusters = 2 to 6).
(5) Assign haplotype labels to strains based in the clustering with the maximum average
silhouette.
(6) Derive consensus haplotypes. For each haplotype cluster, a consensus haplotype is
defined as the string comprised of the most frequent genotype at each SNP position.
(7) Compare the consensus haplotypes to the actual SNP genotypes.
(8) If the number of errors is greater than 1 then go to (9), otherwise go to (10).
(9) Remove the most recently added SNP from the current block. Store the haplotyping
results from the previous iteration. Start a new block with the current SNP. Go to (3).
(10) Add the next consecutive SNP to the current block. Go to (4). If there are no more
SNPs on the current chromosome, select a new chromosome and go to (2). The
computation is complete when all chromosomes have been analyzed.
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SNP-based distances between strains are computed as the sum of SNP differences between
strains. The range of number of haplotypes per block to allow was selected based on the
estimated number of ancestral haplotypes44.
GEP expression profiling was previously described22 and is available at GEO under
accession GSE10656. This data is referred to as kit+/lineage- (KL) throughout the text.
Hypothalamus and adipose were obtained from GEO (accessions GSE5961 and GSE8028,
respectively). For clustering and network analysis, probes were first filtered based on detection.
In the KL data, a probe was considered detected in a sample if its signal was greater than a set of
negative controls on the Illumina array. 13,496 probes were detected in all biological replicates of
at least three strains (excluding C3H, for which only one array was analyzed). Only the 14,871
and 10,040 probes that were detected as present in at least 25% of the strains in the
hypothalamus and adipose data sets, respectively, were kept for clustering analysis.
Unsupervised hierarchical clustering was performed with R’s hclust function, using 1-Pearson
correlation as the distance metric and the complete linkage method for node merging. To assess
the non-randomness of the strains clustering according to susceptibility status, we computed the
ratio of the mean distances of among susceptible strains to the mean of the distances between all
susceptible and resistant strains. Then, we permuted the strain labels 10,000 times, and
recomputed the ratio of distances. The P-value of the observed clustering is the number of
random permutations in which the distance test statistic >= observed distance test statistic
divided by 10,000. This analysis was performed on the median expression profiles of strain
replicates, only in those strains in which the susceptibility status is known. SNP clustering was
based on strain-strain pair-wise distances computed by counting the number of SNPs that differ
between each the strains divided by the total number of SNPs that are typed in both strains.
Strains with unknown susceptibility status were not included in the differential expression
analysis. We used the limma package in R to model the expression of each gene with
coefficients representing strain replicates and susceptibility status45,46 and the false discovery rate
(FDR) was estimated using q-value47. All of the 976 significant probes were detected as present
in at least 50% of either the susceptible or resistant strains. Association of module eigengenes
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with susceptibility was tested in the same way as differential expression. Enrichment analysis
was performed using DAVID48. Only the GO annotations Biological Process 5 and KEGG
pathways were assessed. We only report annotations that pass an FDR threshold < 25%.
Expression data from all 20 strains previously profiled were used in expression network analysis.
Anchored expression networks were identified by searching for probes that exhibited expression
profiles that were significantly correlated with driver gene expression at an FDR threshold < 1%.
Normalized gene expression data used for validation of eQTLs and anchored modules
was downloaded from GEO (GSE18067). This data set includes profiling on sorted (purified)
hematopoietic stem, progenitor, myeloid and erythroid populations from female BXD recombinant
inbred mice28. This data is referred to as Gerald de Haan (GdH) throughout the text. Only
detection calls, coded as 0 for absent or 1 for present, were used to globally compare our KL data
to GdH. Clustering was performed using the same parameters as described above for the KL
data. KL eQTLs were validated by testing the association between the genotypes of SNPs within
2 Mb of driver genes and driver gene expression in each compartment separately. Genotypes
were treated as factors in a linear model of driver gene expression. P-values of the resulting Fstatistics were adjusted for multiple testing using Holm’s method49. Drivers that had corrected Pvalues < 0.05 in at least one compartment were considered validated. Assessing the
reproducibility of the association between driver and response gene expression was performed in
a similar manner. A linear model of response gene expression was fit with driver gene
expression as the dependent variable (one model per driver-response gene pair per
compartment). In this case, Benjamini and Hochberg’s method to control the false discovery rate
was applied to the resulting p-values50. WGCNA analysis was performed as previously described
using the R package WGCNA30. Briefly, β values for calculating the weighted network adjacency
were selected based on the power at which the scale law R2 exceeded 0.9. Weighted adjacency
matrices were computed, modules were defined using the cutTreeDynamic function (which
selects good dendrogram cutoffs) and similar modules were merged using mergeCloseModules
(which compensates for the high sensitivity of WGCNA). Eigengenes were computed as the first
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principal component of a module’s expression matrix. Eigengenes were tested for differential
expression between susceptible and resistant as described above for individual genes.
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Table 1: Functional Enrichment of Differentially Expressed Genes
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P-Value
Fold
Annotation name
Count (nominal) Enrichment FDR (%)
apoptotic program
11
9.58E-05
4.71
0.17
protein modification process
88
1.77E-04
1.46
0.31
hexose metabolic process
15 0.00107053
2.76
1.88
monosaccharide metabolic process
15 0.00129867
2.71
2.28
intracellular transport
43 0.00182315
1.63
3.18
Pyrimidine metabolism
11 0.00325706
2.98
3.99
negative regulation of cellular metabolic process
25 0.00230736
1.95
4.01
nucleotide metabolic process
18 0.00246768
2.27
4.29
nucleoside triphosphate biosynthetic process
9 0.00286827
3.68
4.96
negative regulation of nucleobase, nucleoside,
GO:0045934
22 0.00335044
2.00
5.78
nucleotide and nucleic acid metabolic process
GO:0006915
apoptosis
39 0.00643571
1.56
10.81
mmu05210
Colorectal cancer
10 0.00953927
2.74
11.28
GO:0008637
apoptotic mitochondrial changes
5 0.00751505
6.23
12.52
GO:0006396
RNA processing
25 0.00852521
1.76
14.08
GO:0009064
glutamine family amino acid metabolic process
6 0.00927287
4.57
15.22
GO:0015031
protein transport
39 0.01063622
1.51
17.27
GO:0019362
pyridine nucleotide metabolic process
5 0.01370052
5.27
21.69
GO:0008219
cell death
39 0.01444197
1.48
22.73
GO:0016481
negative regulation of transcription
19 0.01461908
1.85
22.98
Count: Number of differentially expressed genes with given annotation.
Annotation
GO:0008632
GO:0006464
GO:0019318
GO:0005996
GO:0046907
mmu00240
GO:0031324
GO:0009117
GO:0009142

Table 2: Anchored Susceptibility Modules

A_1

Module

Anchor Gene
LOC634046

KL
460

A_2
A_3
A_4

scl41743.2_361
GI_38089999
A330106M24Rik

A_6
A_7
A_9
A_12
A_14
A_16
A_17

HSC

Progenitor

Myeloid Erythroid Replicated
24
200
237

44

3

402
38
4

141
5
4

273
2
4

208
1
4

20
3
2

330
8
5

Ociad2
GI_46852192-I
Zfp862
A630001G21Rik
Aste1

132
97
106
112
102

64
2
14
80
8

4
16
20
51
49

17
2
2
39
1

11
51
1
49
2

76
55
27
105
53

Ckap2l
H2-Ke6

607
238

5
13

117
110

290
3

5
82

357
153

Association
with
Top GO
Suscetibility
2.25 secretion by cell
regulation of nucleobase, nucleoside,
nucleotide and nucleic acid metabolic
1.09 process
1.72
1.82
regulation of phosphoprotein
1.5 phosphatase activity
1.95 interphase of mitotic cell cycle
2.3
2.38 regulation of transcription
2.67
1.28 DNA repair
1.93

Top Kegg

Ubiquitin mediated
proteolysis

Phosphatidylinositol
signaling system
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A_20
Dusp16
91
46
5
44
31
73
2.08
A_21
scl0217069.13_16
58
4
5
22
5
30
2.72
A_22
Atf7ip
39
2
2
10
11
20
2.61
A_23
Snrpn
4
3
3
1
2
4
0.94
A_24
Atp6v0e2
78
5
6
2
1
6
2.91
A_25
Gimap7
30
4
3
1
7
10
2.35
A_26
Pdzk1ip1
79
40
32
1
21
58
2.35
A_27
Polr1b
27
4
11
5
3
13
3.11
A_28
Magohb
65
56
36
25
48
62
0.97 cellular lipid catabolic process
A_30
Sox13
34
19
26
4
2
30
1.45 fatty acid metabolic process
A_32
Ptcd3
18
8
15
6
5
18
2.68
A_33
Casp9
37
2
1
7
2
7
3.22
A_34
Ctsf
223
54
124
9
72
170
2.34
A_36
scl46617.10.1_4
13
5
4
9
6
11
2.5
A_37
Parp2
88
22
22
18
20
43
2.05
A_38
Hdhd3
178
73
3
71
2
103
1.78
A_39
5830417I10Rik
5
2
4
2
2
4
2.07
A_41
Prcp
3
3
2
3
3
4
2.11
A_43
Ggcx
7
7
8
6
4
8
2.53
KL: Number of Illumina expression probes significantly assoicated with anchored gene expression in kit+/lineage- (KL) cells
HSC: Number of Illumina expression probes in preliminary anchored module significantly assoicated with anchored gene expression in GdH Sca+/kit+/lineage- (HSC) cells
Progenitor: Number of Illumina expression probes in preliminary anchored module significantly assoicated with anchored gene expression in Sca-/kit+/lineage- (Progenitor) cells
Myeloid: Number of Illumina expression probes in preliminary achored module significantly assoicated with anchored gene expression in Gr-1+ (Myeloid) cells
Erythroid: Number of Illumina expression probes in preliminary achored module significantly assoicated with anchored gene expression in TER-119+ (Erythroid) cells
Replicated: Number of Illumina expression probes in preliminary achored module significantly assoicated with anchored gene expression in at least one GdH data set.
Association with Suscetibility: -Log10(P-value)
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39

23,845

Figure 1: Mouse Haplotype Map. (A) Typical haplotype block derived from Broad SNP data.
Rows represent SNPs, ‘=’ are untyped. Columns represent 48 classical inbred strains. Strains
sharing the same haplotype are grouped together and are separated from strains of other
haplotypes by ‘|’. Given the strain haplotypes, it is possible to predict the all typed genotypes with
at most a single error. The distribution of the number of SNPs (B) and haplotypes (C) per block.
The number of CNVRs that are accurately predicted by neighboring haplotype blocks is relatively
low (D).
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Figure 2: Gene Expression Profiling of Hematopoietic Stem and Progenitor Cells in t-AML
Resistant and Susceptible Strains of Mice. (A) Unsupervised clustering of Illumina probes
that are present in at least 3 strains largely separates susceptible (blue) from resistant (red)
strains. Susceptibility status of some strains is undetermined (grey). (B) Differentially expressed
genes are enriched in apoptosis-related genes. Heatmap of differentially expressed genes
involved in apoptosis.
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Figure 3: Anchored Susceptibility Networks. (A) Anchored modules are represented as
nodes. Edges between modules represent network eigenegene correlation. Low and negative
correlations are not shown for clarity. Edges between the ‘Susceptiblity’ and anchored network
nodes represent association between network eigengenes and susceptibility status. Node size
indicates the number of response genes in the anchored network. (B) Module A_16, anchored by
Ckap2l, is enriched in cell cycle- and DNA damage-annotated genes. Green nodes represent
genes with lower expression in susceptible strains, red nodes represent genes with higher
expression in susceptible strains. Correlations among response genes, represented as edges,
are only display for those relationships where the Pearson correlation > 0.5. (C) Log2-ratio plot
indicating the presence of a CNVR approximately 150 kb from Parp2, the anchor gene for module
A_37. (D) Module A_37, includes 10 genes located with 7 Mb of the CNVR depicted in Figure
3C.

139

(A)

140

(B)

141

(C)

142

(D)

143

Supplementary Figure 1: Strain Dendrograms. Unsupervised clustering of strains using the
strain median expression profile (A) groups strains by susceptibility status to an extent greater
than expected by chance (see text), and differently than when clustering gene expression profiles
of the hypothalamus (B), adipose (C), and when clustering based on SNP-based distance (D).
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Supplementary Figure 2: Differential gene expression. There are approximately 1,000 genes
differentially expressed between susceptible and resistant strains.
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Supplementary Figure 3: Gene Expression Profiling of Hematopoietic Cells from BXD
Mice. Unsupervised clustering of Illumina detection calls groups expression profiles according to
compartment (Erythroid: orange, Myeloid: navy blue, Hematopoietic stem cells (HSC): red,
Progenitors: royal blue, KL cells: green), and correctly places KL samples between Progenitors
and Stem cell samples. Two HSC samples are outliers.
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Conclusion

The achievements of this thesis work include the development of novel software for the detection
and genotyping of CNVs, determining the copy number content CNVs to a 10-kb resolution in 20
inbred mouse strains commonly used in biomedical research, the development of an inbred
mouse haplotype map, the mapping of both CNV- and SNP-based hematopoietic stem and
progenitor cis-eQTLs, and the identification of candidate coexpression networks that underlie tAML susceptibility. There are several findings that are of interest in the fields of cancer
susceptibility and genetics.

DNA Copy number variation

We developed wuHMM to detect CNVs and demonstrated its performance characteristics. A
novel aspect of this software is that it can use SNP information to improve its sensitivity in
detecting small CNVs when abundant sequence divergence exists between the genomes under
comparison. wuHMM has been utilized in other studies1 (other manuscripts in preparation), and
has been cited in other studies as a novel application of HMMs in CNV detection2-4. The advent
of next-generation provide a new means of identifying CNVs5 by read depth coverage.
Theoretically, re-sequencing at a high coverage will improve CNV resolution down to a base pair
level. Due to technical and cost constraints at present, it is unlikely that aCGH will become
obsolete in the near-term. Further, because wuHMM uses emission distributions of discrete
variables, it is theoretically possible to directly apply wuHMM on read-count data for CNV
detection. The extent to which it would need to be modified and optimized for use on resequencing read data is unknown.
To determine the copy number content of the mouse genome, we performed
comparative genomic hybridization using a long-oligonucleotide array containing approximately
2.1 million probes evenly spaced across the reference C57BL6/J genome (median inter-probe
spacing of 1,015 bases). We applied wuHMM to this data to identify 1,333 CNVRs (82 Mb) at an
empirically estimated false positive rate of less than 5%. Most CNVRs are less than 10 kb in
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length, are found in more than one strain, and, in total, span 3.2% (85 Mb) of the genome. There
are several pressing questions regarding structural variation in mice genomes. Second, are there
tissue-specific CNVs? Our analysis included the comparison of DNA from four tissues of an
individual C57BL6/J mouse. Although we detected no tissue specific copy number alterations, it
does not preclude the possibility that they would be detected in more samples, different tissues,
or using a higher resolution platform. Third, what is the age of CNVs relative to the SNP-based
haplotypes? Are CNVs coming and going in the genomes of these putatively identical and
homozygous strains of mice? These questions will need to be addressed by genotyping CNVRs
and neighboring SNPs in a large number of individual mice from identical strains across multiple
generations.
To assess the potential functional impact of copy number variation, we mapped
expression profiles of purified hematopoietic stem and progenitor cells (data which we
generated), adipose tissue and hypothalamus (data in public domain) to CNVRs in cis. Of the
more than 600 significant associations between CNVRs and expression profiles, most map to
CNVRs outside of the transcribed regions of genes. Presumably, the remaining CNVR eQTLs
reflect expression variation mediated by alteration of regulatory material or local chromatin
structure. This would be consistent with a model where alterations in expression patterns are
better tolerated than complete or partial gene gains or losses. This observation refutes the prior
prediction that the major impact of CNVs on expression would be through gene dosage effects6.
The distant impact of CNVs on local expression variation was corroborated by an independent
study of CNVs and expression variation in multiple mouse tissues7. Multiple studies have cited
this mechanism to explain associations between CNVRs and phenotypes: GSTT2B expression
variation8, hypertrichosis9, and Pea-comb phenotype10. It is difficult to prove that a non-gene
dosage CNV causes an expression change. The development of a general framework for testing
the link between CNV and expression would be beneficial. It would help to define the
characteristics of the CNV sequences (or structures) that play a role in expression regulation, and
could facilitate the development of genetic modifications for altering gene expression.

153

We found that in hematopoietic stem and progenitor cells, up to 28% of strain-dependent
expression variation is associated with copy number variation, supporting the role of germ line
CNVs as major contributors to natural phenotypic variation in the laboratory mouse. Some of the
CNVR eQTLs reported here may be in linkage disequilibrium with another allele causing the
associated expression change, underscoring the need to characterize the relationship between
CNVs and other genetic variants. It is likely that there are additional eQTLs not detected here:
CNVRs that alter expression in only one or two strains, trans eQTLs, eQTLs that associate with
genes expressed in tissues not sampled here, and eQTLs with weak effects. Increasing the
number of strains and the tissues sampled would address some of these limitations. However,
extending this work to a much larger population with greater genetic diversity (i.e., the
Collaborative Cross11) would increase the power to detect trans and weaker effects and therefore
enable a clearer understanding the overall impact of CNVR on expression variability.

Therapy-related AML

The overarching goal of the thesis, to expand what is known about the processes underlying
susceptibility to t-AML, has been met by the integrated genomics study presented in Chapter 4.
We identified novel candidate expression networks associated with susceptibility and the putative
upstream regulators of these modules. The biological processes implicated include apoptosis,
DNA repair (including base excision repair), and cell cycle regulation. Each of these annotations
are biologically plausible, given what is known about t-AML susceptibility, and warrant further
experimental exploration. The networks were validated at several levels. First, the association
between cis-markers and gene expression was assessed in independent data sets. eQTLs not
reproduced were dropped from further analysis. Second, since we hypothesized that anchor
genes drive expression of response genes, we also tested this association in independent data
sets. Again, we removed those genes where an association was not reproduced, resulting in
well-validated coexpression networks. We did not validate the role of expression networks in tAML susceptibility as these sets of experiments will be long term-projects that extend beyond the

154

scope of this thesis. However, we have initiated the validation of the driver status of the Ckap2l
module (enriched in cell cycle and DNA repair genes). In these studies, we are knocking down
the expression of Ckap2l in purified KL cells and assessing the expression of the network after 24
and 48 hours. We predict that knockdown of Ckap2l in C57BL/6J (t-MDS/AML resistant) cells will
recapitulate the susceptible strain expression pattern of the Ckap2l module, proving that Ckap2l
regulates (directly or indirectly) the cell cycle/DNA repair network. If successful, then this
paradigm will serve as a powerful method both to validate drivers of networks and to modulate
network activity. Ultimately, the contribution of these networks to t-AML susceptibility will need to
be tested formally. The ability to modulate network activity by altering driver gene expression will
serve as a powerful tool in the costly and lengthy experiments that assess causality in t-AML
susceptibility.
The development of a t-AML susceptibility classifier (or predictor) based on pre-exposure
transcriptional profiles and anchored modules would be a valuable extension of the current work.
Predictors could be tested by assessing the susceptibility of the BXD cross, for which extensive
SNP and expression profiling data already exist. Ultimately, the development of highly accurate
classifiers for human t-AML susceptibility would be valuable in a clinical setting. But in the near
term, an accurate mouse classifier would be beneficial because it would enable the use of preexposure transcriptional profiles as a biomarker. This is practically important because the latency
of t-AML can be up to 16 months. This imposes significant cost and time constraints on these in
vivo experiments.
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